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Autophagy Restricts HIV-1 Infection by Selectively Degrading Tat in
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ABSTRACT
Autophagy is a ubiquitous mechanism involved in the lysosomal-mediated degradation of cellular components when they are
engulfed in vacuoles called autophagosomes. Autophagy is also recognized as an important regulator of the innate and adaptive
immune responses against numerous pathogens, which have, therefore, developed strategies to block or use the autophagy ma-
chinery to their own benefit. Upon human immunodeficiency virus type 1 (HIV-1) infection, viral envelope (Env) glycoproteins
induce autophagy-dependent apoptosis of uninfected bystander CD41 T lymphocytes, a mechanism likely contributing to the
loss of CD41 T cells. In contrast, in productively infected CD41 T cells, HIV-1 is able to block Env-induced autophagy in order
to avoid its antiviral effect. To date, nothing is known about how autophagy restricts HIV-1 infection in CD41 T lymphocytes.
Here, we report that autophagy selectively degrades the HIV-1 transactivator Tat, a protein essential for viral transcription and
virion production. We demonstrated that this selective autophagy-mediated degradation of Tat relies on its ubiquitin-indepen-
dent interaction with the p62/SQSTM1 adaptor. Taken together, our results provide evidence that the anti-HIV effect of au-
tophagy is specifically due to the degradation of the viral transactivator Tat but that this process is rapidly counteracted by the
virus to favor its replication and spread.
IMPORTANCE
Autophagy is recognized as one of the most ancient and conserved mechanisms of cellular defense against invading pathogens.
Cross talk between HIV-1 and autophagy has been demonstrated depending on the virally challenged cell type, and HIV-1 has
evolved strategies to block this process to replicate efficiently. However, the mechanisms by which autophagy restricts HIV-1
infection remain to be elucidated. Here, we report that the HIV-1 transactivator Tat, a protein essential for viral replication, is
specifically degraded by autophagy in CD41 T lymphocytes. Both Tat present in infected cells and incoming Tat secreted from
infected cells are targeted for autophagy degradation through a ubiquitin-independent interaction with the autophagy receptor
p62/SQSTM1. This study is the first to demonstrate that selective autophagy can be an antiviral process by degrading a viral
transactivator. In addition, the results could help in the design of new therapies against HIV-1 by specifically targeting this
mechanism.
Macroautophagy, herein referred to as autophagy, is a majorcellular catabolic pathway highly regulated in eukaryotes. It
is involved in the degradation of cytoplasmic material after its
sequestration in vacuoles called autophagosomes. The autopha-
gosomes fuse with lysosomes to form autolysosomes in which the
sequestered material is degraded and then recycled (1). Since the
discovery of the Atg genes that regulate this process, autophagy
has been found to be involved in a number of important cellular
functions, including cellular homeostasis, development, aging, or
innate and adaptive immune responses (2, 3). Autophagy is be-
lieved to be one of the most ancient defense processes against
invading pathogens. Its antiviral effect has been described inmany
studies through different mechanisms, including a direct degra-
dation of cytoplasmic viral components, as shown, for example
for the Sindbis virus (SIN) capsids that are specifically targeted to
autophagy upon interaction with p62 (4, 5). Importantly, patho-
gens have evolved different means to inhibit or use autophagy to
their own profit (6).
At themolecular level, two signaling complexes are involved in
the induction, the elongation, and the closure steps of autophagy,
leading to the formation of autophagosomes. Briefly, the class III
phosphatidylinositol 3-kinase (PI3K), associated with p150 and
beclin 1, is responsible for the formation of the phagophore. Two
ubiquitination-related conjugation systems, leading to the forma-
tion of the Atg12-Atg5-Atg16L complex and the Atg8-phosphati-
dylethanolamine (PE) complex, are required for the elongation
and closure of the autophagosome. These two conjugates are
formed upon the action of a unique E1-activating enzyme called
Atg7. ATG8-PE is inserted in the autophagic vacuole membranes
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and is present all along the pathway, a characteristic that makes it
an autophagosomal marker. As autophagy proceeds, ATG8-PE is
finally degraded in autolysosomes. Six orthologs of ATG8 exist in
mammals, three microtubule-associated protein 1 light chain 3
(LC3) proteins (LC3A, -B, and -C), one gamma-aminobutyrate
receptor-associated protein (GABARAP), and two GABARAP-
like proteins (GABARAPL1 and GATE16/GABARAPL2). All of
these proteins are synthesized as precursors that are rapidly pro-
cessed at their C termini, leading to the exposure of a glycine
residue that can be conjugated to PE (7–9). LC3B is still the most
extensively studied ATG8 protein and will be referred to hereafter
as LC3.
Autophagy can be a very selective process by the action of adap-
tor proteins behaving as autophagy cargo receptors, themselves
degraded by autophagy due to their interaction with LC3 (10).
Autophagy cargo receptors share at least one domain, the LIR
domain (LC3-interacting region), allowing interaction with ATG8
family members and thus targeting the cargos to autophagosomes
(11). p62/SQSTM1 (sequestosome 1, hereafter called p62) is a typical
autophagy receptor that interactswithubiquitinated substrates via its
UBA domain (ubiquitin-associated domain) and that is able tomul-
timerize via its PB1 domain (NH2-terminal Phox and Bem1p do-
main). These twomotifs are important for selective autophagic deg-
radation of ubiquitinated substrates (10, 12–14). Of note, p62 has
been involved in the lysosomal-mediated degradation of incoming
pathogens, a process termed “xenophagy” (15, 16).
Human immunodeficiency virus type 1 (HIV-1) infects im-
mune cells, mainly CD41 T lymphocytes and macrophages. In
most instances, viral entry is mediated by the interaction of the
viral envelope (Env) glycoproteins (gp120 and gp41) with CD4
and a coreceptor, mainly CCR5 or CXCR4, expressed at the sur-
face of the target cells, to initiate a membrane fusion event. The
gp120 protein interacts first with CD4, triggering conformational
changes leading to increased exposure of gp120 regions able to
bind to the coreceptor. This interaction induces a structural rear-
rangement in gp41 and the insertion of its N terminus fusion
peptide into the target cell membrane, leading to the fusion be-
tween viral and cell membranes and thus to viral entry (17). The
RNA viral genome is then retro-transcribed in DNA by the viral
reverse transcriptase and is transported to the nucleus, where it
integrates the genome of the host cell by the action of the viral
integrase. After the integration step, the viral transactivator Tat
enables the transcription of the viral DNA, leading to the pro-
duction of the viral components necessary to synthesize new
infectious particles that are released from the infected cells.
The HIV-1 replication cycle can thus be divided in two phases: the
early phase, from viral entry to provirus integration, and the late
phase, from transcription of viral genes to the release of new viral
particles (18, 19).
Tat is a small HIV-1 protein of 80 to 103 amino acids, depend-
ing on the viral strain, necessary for the transcription of all the
viral genes after its binding to the TAR RNA loop present in the
HIV-1 long terminal repeat (LTR) promoter (20). In addition to
its role in infected cells, Tat can be secreted and captured by by-
stander cells, where it can induce apoptosis or modulate the ex-
pression of cellular proteins, in particular, proinflammatory cyto-
kines (21–24).
Complex links exist betweenHIV-1 and autophagy, depending
on the cell types and on the infectious status of the target cell type,
i.e., if the target cell is productively infected or not (25–27). In
dendritic cells, HIV-1 is able to block autophagy, impeding viral
antigen presentation (28, 29). In CD41 T lymphocytes, we previ-
ously demonstrated that autophagy is induced by the gp41 fuso-
genic function and that this process leads to apoptosis of unin-
fected bystander CD41 T cells, i.e., cells that have been in contact
with infected cells without being productively infected (30, 31). In
contrast, autophagy is blocked in productively infected CD41 T
cells (32).
In macrophages that have been challenged by the virus but not
productively infected, autophagy is inhibited via the activation of
Stat3 and Src-Akt by Tat and interleukin-10 (IL-10) (33). HIV-1
Tat also suppresses STAT1 activation triggered by gamma inter-
feron (IFN-g) in monocytes and IFN-g-induced autophagy in
primary macrophages, suggesting that inhibition of autophagy
could impair the immune defenses by blocking the antigen pro-
cessing required for the recognition and killing of intracellular
pathogens (34). These results are consistentwith the fact thatmac-
rophages do not undergo Env-mediated apoptosis and are not
subjected to depletion during HIV-1 infection.
The mechanism by which autophagy exerts its restriction ac-
tivity against HIV-1 infection in CD41 T cells remains to be fully
characterized. We demonstrate here that p62 interacts with Tat
and targets it to lysosomal-mediated degradation via selective au-
tophagy. This interaction is not mediated by a conventional do-
main of p62 since theUBAor the PB1 domain of this protein is not
involved. Interestingly, both neo-synthesized Tat in infected cells
and exogenous Tat internalized by uninfected cells are sensitive to
autophagic degradation, indicating that all the functions of Tat
could be counteracted by autophagy. In conclusion, we propose
that degradation of the viral transactivator Tat by selective au-
tophagy is a potent though unrecognized antiviral cellular mech-
anism against HIV-1 infection of CD41 T lymphocytes.
MATERIALS AND METHODS
Ethics statement. Primary CD41 T cells were purified from blood ob-
tained from the Etablissement Français du Sang (EFS). Procedures using
human cells were approved by the Human Experimentation and Ethics
Committee of the CNRS Institute. TheHIV-1 infection experiments were
performed in a biological safety level 3 laboratory. Cell culture was per-
formed in a biological safety level 2 laboratory.
Cell culture. The original HEK.293T cell line, HEK cells expressing
wild-type (WT) CD4 and wild-type CXCR4 (HEK/CD4/CXCR4), and
HEK cells stably expressing Env at the their surface were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with antibiot-
ics and 10% fetal calf serum (FCS). MAGIC5B cells (cell line expressing
CXCR4 and CCR5 and bgalactosidase under the control of the HIV long-
terminal repeat [LTR]) were obtained from T. Masashi (Tokyo, Japan)
and cultured in DMEM supplemented with antibiotics and 10% FCS.
MOLT cells are nonadherent human acute lymphoblastic leukemia cells.
The chronically HIV-1-infected MOLT cells (MOLT-X4) and the unin-
fected parental cell line (MOLT) were provided by J. Blanco (Barcelona,
Spain). The 8.E5 cell line is a CEM-derived T cell line containing a single
integrated copy of HIV-1 and unable to produce infectious virions. T cell
lines were cultured in RPMI 1640medium supplemented with antibiotics
and 10% FCS. Primary CD41 T cells were isolated from peripheral blood
mononuclear cells and purified by negative selection using the CD41
Rosette separation technique (Stem Cell Technologies). Cells were phe-
notypically analyzed, stimulated with 2 mg of phytohemagglutinin (PHA)
for 24 h, and maintained in culture by the addition of 100 U/ml of inter-
leukin 2 (IL-2) (Boehringer Mannheim) every 2 to 3 days.
Reagents and Abs. Torin 1 (To) was purchased from Tocris, and
3-methyladenine (3-MA), PHA, E64d, and pepstatin A (anti-protease
Sagnier et al.
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[AP]) were purchased from Sigma-Aldrich. T20 was obtained from the
NIH AIDS Reagent Program. Anti-LC3 (catalog no. L7543), anti-glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH; catalog no. G9545),
anti-ATG7 (catalog no. A2856), and anti-FLAG-horseradish peroxidase
(HRP) (catalog no. A8592) were obtained from Sigma-Aldrich; anti-Tat
(catalog no. sc65912) and anti-beclin 1 (catalog no. sc11427) were pur-
chased from Santa-Cruz Biotechnologies. The monoclonal anti-p24 anti-
body (Ab) was from the NIH AIDS Reagent program.
Plasmids. The pNL4-3 molecular clone was obtained from the NIH
AIDS Reagent Program. The different p62 constructs, cloned in a pENTR
plasmid, were a kind gift from Terje Johansen (University of Tromsø,
Tromsø, Norway). After an LR Clonase reaction, we cloned the different
p62 cDNAs in pDEST vectors in order to obtain glutathione S-transferase
(GST)-fused proteins, using Gateway cloning technology (Life Technol-
ogies). The LC3B cDNA was first cloned in a pENTR vector and then
cloned in a pDEST vector using Gateway cloning technology (Life Tech-
nologies). TheGST-LC3 F52Amutant was obtained bymutagenesis using
a QuickChange kit from Stratagene. The FLAG-tagged Tat (86 residues;
BH10 isolate) was cloned in the pBi-GL expression vector under the con-
trol of a tetracycline response element (TRE) (the FLAG tag is placed at the
C-terminal part of Tat). To express the gene of interest, the plasmid needs
to be cotransfected with a pUHD-neo vector responsible for the expres-
sion of the tTA regulatory proteins needed to transactivate the TRE. A
pBi-Tat K50/51A mutant expressing the FLAG-Tat K50/51A mutant was
generated from pBi-Tat using a QuickChange kit from Stratagene (35).
The FLAG-Tat K71R expression vector was a kind gift from Monsef Ben-
kirane (as with pBi-GL-Tat, the FLAG tag is located at the C terminus of
Tat) (36).
The different constructs expressing Vif, Nef, and Vpr were cloned in a
pENTR plasmid and transferred in a pCI-neo33FLAG expression vector
after an LR Clonase reaction using Gateway cloning technology (Life
Technologies). The expression vector coding for GFP-LC3 (where GFP is
green fluorescent protein) was kindly provided by T. Yoshimori (Osaka
University, Japan) and R. Willey (NIAID, NIH). The expression vector
coding for Gag was kindly provided by Nathalie Chazal (Centre d’Études
d’Agents Pathogènes et Biotechnologies pour la Santé [CPBS], Montpel-
lier, France) (37).
TEM analysis. Cells were fixed in situ with 2.5% glutaraldehyde in
cacodylate buffer (pH 7.4) for 60 min at 4°C, postfixed with 2% osmium
tetroxide, and then washed in cacodylate buffer containing 0.5% tannic
acid. After extensive washes in 0.1M Sorensen phosphate buffer (pH 7.2),
cells were included in a fibrin clot as described by Charret and Fauré-
Fremiet (38). Cells were then postfixed with 2% osmium tetroxide and
0.5% tannic acid, dehydrated, and embedded in Epon (Embed-812; Elec-
tronMicroscopy Sciences, Inc.). Sectionswere counterstainedwith uranyl
acetate and lead citrate and examined with a Hitachi H7100 transmission
electron microscope (TEM).
HIV-1 infection and production. To produce HIV virions, HEK cells
were transfected with pNL4-3, and supernatants were collected at 2 days
posttransfection. Viral particles were concentrated by ultracentrifugation.
Jurkat cells were then challenged for 24 h with dilutions of the concen-
trated viruses. Flow cytometry analysis of Gag1 cells was performed in
order to quantify the multiplicity of infection (MOI). Quantification of
viral particle production was performed with a p24 enzyme-linked
immunosorbent assay (ELISA) from Innogenetics (Innotest HIV anti-
gen monoclonal Ab [MAb]) according to the manufacturer’s instruc-
tions. CD41 T cells were infected with concentrated viruses at an MOI
between 0.1 and 1. Coculture experiments were done with chronically
HIV-infected (MOLT-X4) or uninfected (MOLT) T cells coincubated for
indicated times (see the figure legends) with HEK/CD4/CXCR4 or
MAGIC5B cells. Quantification of HIV infection of target cells was mea-
sured by flow cytometry (for HEK cells) or b-galactosidase activity assay
(for MAGIC5B cells).
GST pulldown experiments. Constructs expressing GST proteins
fused to wild-type LC3 (GST-LC3), mutated LC3 (GST-LC3 F52A), wild-
type p62 (GST-p62), or mutated p62 (GST-p62DLIR, GST-p62DUBA,
and GST-p62DPB1, with deletions of the LIR, UBA, and PB1 domains,
respectively) were cotransfected in HEK cells with the pBi-FLAG-Tat and
pUHDvectors. Corresponding empty vectors were used as controls. Anti-
proteases (E64d plus pepstatin A) were added to the transfected cells in
order to optimize the expression of Tat. Cell lysis was performed at 24 h
posttransfection in 150 mMNaCl, 20 mM Tris, pH 7, and 0.5% NP-40 at
4°C. After centrifugation for 20 min at 4°C, the lysates were incubated
with glutathione-conjugated Sepharose beads for 2 h at 4°C. Unbound
proteins were removed by four washes with cold lysis buffer. Bound pro-
teins were then eluted by boiling for 10 min in Laemmli buffer and sepa-
rated by gel electrophoresis, followed by immunoblotting with specific
antibodies.
Flow cytometry. The percentage of HIV-1-infected cells was deter-
mined by quantifying the cellular levels of p24Gag by flow cytometry using
anHIVKC57 fluorescein isothiocyanate (FITC) kit according to theman-
ufacturer’s instructions (Beckman Coulter). Briefly, cells were fixed and
permeabilized, and the anti-p24 antibody was added to the cells. After
staining for 30 min, cells were washed with phosphate-buffered saline
(PBS), and fluorescence intensity was measured on a Coulter Epics XL
Flow Cytometer (Beckman Coulter).
b-Galactosidase assay. A chemiluminescent reporter assay system,
Galacto-Star b-Galactosidase Reporter Gene Assay System for Mamma-
lian Cells, from Life Technologies, was used to quantitate ß-galactosidase
activity according to the manufacturer’s instructions. Briefly, 0.5 3 106
MAGIC5B cells were lysed in 200 ml of lysis buffer provided by the man-
ufacturer. Fifty microliters of cell lysate was used in each assay, in dupli-
cates. The results were normalized by quantifying the total protein con-
centrations using a Bradford assay from Sigma-Aldrich.
Transfections. A total of 0.5 3 106 HEK or HEK/CD4/CXCR4 cells
were cultured in six-well plates 24 h prior to transfection. Plasmids were
then transfected using TurboFect reagent (Fermentas) according to the
manufacturer’s instructions. Smartpool p62 small interfering RNA
(siRNA) and control siRNA (siCT) were from ABgene. Beclin 1 siRNA
and Atg7 siRNA were synthesized and annealed by Eurogentec. The
mRNA sequences to be targeted for beclin 1 and Atg7 siRNAs were 5=-C
AGUUUGGCACAAUCAAUA-3= and 5=-GCAUCAUCUUCGAAGUGA
A-3=, respectively. Transfection of siRNA into HEK/CD4/CXCR4 or
MAGIC5B cells (0.5 3 106 cells maintained in six-well plates) was per-
formed with LipoRNAiMax reagent (Invitrogen) according to the
manufacturer’s instructions. In the case of siRNA and plasmid
cotransfections, 0.25 3 106HEK cells were first transfected with siRNA
using LipoRNAiMax reagent, and, 24 h later, siRNA-transfected cells
were transfected with the plasmid using TurboFect reagent.
Western blotting. Cell lysates were loaded in 12% Prosieve 50 gels
(Lonza) and transferred to polyvinylidene (PVDF) membranes. After a
blocking step for 1 h at room temperature in PBS containing 0.5% casein,
membranes were incubated overnight at 4°C with the primary antibody
(Ab) in the blocking buffer. After three washes with PBS supplemented
with 0.05% Tween, the membranes were incubated for 1 h at room tem-
perature with peroxidase-coupled secondary Ab. Upon extensive washes,
membranes were incubated with LuminataWestern HRP Substrate (Mil-
lipore). Proteins were detected by chemiluminescence and imaged with a
G-box camera (Syngene imaging system). The expression level ofGAPDH
was used as a loading control in all of the Western blotting experiments
and for quantification. Quantification of protein expression was done
with Genesys software (Syngene).
The form of LC3 conjugated to PE, named LC3-II, presents a higher
electrophoretic mobility in gels and was, therefore, used to quantify au-
tophagy.
Fluorescence analysis of autophagy. HEK/CD4/CXCR4 cells were
cultured in six-well plates and transfected with pEGFP-LC3 using Turbo-
Fect reagent (Fermentas) according to the manufacturer’s instructions.
Transfected cells were then left to adhere on coverslips before coculture
with MOLT cells (negative control) or chronically infected cells (MOLT-
HIV-1 Tat Is Selectively Degraded by Autophagy
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X4) for the indicated times (from 2 h to 48 h) (see Fig. 4A). Human
primary CD41 T cells were transfected with pEGFP-LC3 using a Nucleo-
fector apparatus (Amaxa Biosystems) according to the manufacturer’s
instructions. Transfected primary T cells were then cocultured on cover-
slips for 4 h with effector cells either expressing or not expressing the viral
envelope at their surface (HEK.Env orHEK cells, respectively). Coverslips
were washed with PBS, and cells were fixed in a 3.7% paraformaldehyde-
PBS solution for 10min at room temperature and analyzed by epifluores-
cence using a Leica microscope. Autophagic cells were defined as cells
containing at least five GFP-LC3 puncta. More than 100 transfected cells
were analyzed by twodifferent investigators. Results are fromat least three
independent experiments.
Statistics. Analysis of the variance of the results was performed after
arc sine transformation of the datawhenpercentageswere compared (39).
RESULTS
Induction of autophagy decreases viral production in HIV-1-
infected CD41 T lymphocytes. We, along with others, have pre-
viously shown that autophagy is blocked in productively HIV-1-
infected CD41 T lymphocytes, suggesting that autophagy is an
anti-HIV process counteracted by this virus (32, 40). To examine
this hypothesis, activated primary CD41 T cells were infected by
HIV-1 for 3 days (;20% infection). Then, autophagywas induced
by adding torin 1, an inhibitor of the mTOR kinase, for 24 h. The
level of viral particle production was measured by quantifying the
viral capsid protein p24 by ELISA. As expected, we detected a
significant decrease ofHIV-1 p24 levels in the supernatants of cells
treated with torin 1 (Fig. 1A). The same results were obtained
when torin 1 was added to infected Jurkat cells (Fig. 1B) or chron-
ically infected CD41 T cells (MOLT-X4) (Fig. 1C). Thus, addition
of torin 1 decreases viral production, supporting the anti-HIV role
of autophagy.
Tat interacts with p62 and is specifically degraded by torin
1-induced autophagy. We performed a two-hybrid screen to an-
alyze the interactions between several HIV-1 proteins (Tat, Vif,
Vpr, and Nef) and a bank of ATG proteins. Among the viral pro-
teins tested, the transactivator Tat was the only viral protein able
to bind p62 (data not shown), which is highly suggestive of a role
for selective autophagy. This interaction was further confirmed in
vitro using a GST pulldown assay in which Tat was found to inter-
act with GST-p62 but not GST alone (Fig. 2A). As p62 is an au-
tophagy receptor involved in the specific degradation of proteins
or organelles by autophagy, we then analyzed whether induction
of autophagy could affect the expression level of Tat. To this end,
we transfected human embryonic kidney (HEK) cells with a plas-
mid expressing a FLAG-Tat construct, and autophagy was in-
duced upon addition of torin 1 for 3 h. We observed a significant
decrease in Tat levels upon torin 1 treatment (Fig. 2B). Impor-
tantly, this effect was reversed in cells pretreated with a cocktail of
anti-proteases ([APs] E64d plus pepstatin A) previously described
to block lysosomal-mediated degradation (Fig. 2B). Furthermore,
inhibition of lysosomal proteases, in the absence of autophagy
induction, led to increased levels of Tat expression in cells, sug-
gesting that the viral transactivator can be degraded by lysosomes
(Fig. 2B and D). The levels of the ectopically expressed viral pro-
teins Gag, Vif, and Nef were not affected by the addition of torin 1
(Fig. 2C). These data strongly suggest that the torin 1-induced
decrease in Tat level is selective and relies on an autophagy-
dependent lysosomal-mediated degradation. The results were
confirmed in a context of viral infection using HIV-1 chronically
infected T cells (MOLT-X4 cells) which constitutively produce the
viral Tat protein. As shown in Fig. 2D, Tat levels were also de-
creased inMOLT-X4 cells upon torin 1 treatment for 3 h, and the
autophagy-inducing drug effect could be reversed by AP treat-
ment. Since Tat is essential for the HIV-1 replication cycle, these
results extend further those presented in Fig. 1, in which drug-
mediated induction of autophagy strongly decreased viral release.
To confirm that the autophagic process is responsible for the
lysosomal-mediated degradation of Tat, we downregulated the
expression of the essential autophagy-related protein ATG7 using
siRNA. As shown in Fig. 2E, while the control siRNA did not
prevent torin-1-induced Tat degradation, the viral transactivator
expression levels were significantly increased in cells for which
ATG7 expression was reduced. Notably, even if siRNA-mediated
ATG7 decreased expression was only 30%, Tat levels became to-
tally insensitive to torin 1 treatment, confirming the contribution
of the autophagy pathway in Tat degradation. This result also
indicates that this process is finely tuned and relies on a fully
functional autophagy process.
Since we observed that Tat was interacting with p62 (Fig. 2A),
we aimed at analyzing Tat levels when p62 expression was de-
creased. Remarkably, we noted that the siRNA-mediated decrease
of p62 expression correlated with a significant increase in Tat pro-
tein signal compared to levels obtained in lysates from siCT-
FIG 1 Autophagy has an anti-HIV-1 effect in CD41 T lymphocytes. Primary CD41 T cells (A) or Jurkat cells (B) were infected with HIV-1 at an MOI of 1 for
3 days. Cells were then extensively washed to eliminate excess free viruses and cultured for 24 h in the presence of 2mMtorin 1 to induce autophagy.HIVGag-p24
levels were quantified by ELISA in the culture supernatants. (C) Chronically infected MOLT-X4 cells were treated for 24 h with 2 mM torin 1, and the HIV
Gag-p24 concentration was quantified in the culture supernatants by ELISA. Data are representative of triplicates from at least three independent experiments.
CT, control. *, P , 0.05; **, P , 0.01; ***, P , 0.001.
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treated cells (Fig. 2F). Overall, these results demonstrated that the
autophagy pathway significantly contributes to Tat degradation
and that the autophagy receptor p62, shown to interact with Tat,
could confer selectivity in this process.
The interaction between Tat and p62 is ubiquitin indepen-
dent. As we demonstrated that Tat interacts with p62 and since
p62 is known to induce the selective autophagic degradation of
substrates by interacting with LC3, we further analyzed whether
Tat could be present in complexes with LC3. We thus performed
GST pulldown experiments after cotransfection of plasmids ex-
pressing GST-LC3 and FLAG-Tat in HEK cells. As shown in Fig.
3A, Tat coprecipitates with GST-LC3. To assess whether this in-
teraction was p62 dependent, we cotransfected cells with con-
structs expressing FLAG-Tat and a GST-tagged mutant of LC3
unable to interact with p62 (GST-LC3 F52A) (36, 41). We ob-
served that Tat did not coprecipitate with LC3 F52A (Fig. 3A),
indicating that the interaction between Tat and LC3 was indirect
and seemingly regulated by p62. To confirm this hypothesis, we
tested the interaction between Tat and amutated form of p62 that
does not interact with LC3 (GST-p62DLIR). As expected, thismu-
tant still interacted with Tat with an apparently increased efficacy,
which could be explained by the lack of targeting to autophagy-
mediated degradation and thus a prolonged protein complex sta-
bility (Fig. 3A, lane 6).
The autophagy receptor p62 has been reported to selectively
direct ubiquitinated proteins or ubiquitinated organelles to au-
tophagic degradation via specific recognition of ubiquitin moi-
eties through its UBA domain, and the PB1 domain contributes to
FIG 2 Tat interaction with p62 leads to its selective degradation by autophagy. (A) HEK cells were cotransfected with the FLAG-Tat vector and the GST or
GST-p62 plasmid. At 24 h posttransfection, cells were lysed, and lysateswere subjected toGSTpulldownbefore immunoblottingwith anti-FLAGor anti-GSTAb.
A fraction of lysates was preserved and used as an input control and immunoblotted with the anti-FLAG Ab. The result is representative of at least five different
experiments. (B) HEK cells were transfected with plasmids expressing FLAG-Tat. After 24 h, the transfected cells were either left untreated or treated with 2 mM
torin 1 in the presence or absence of anti-proteases (APs; E64d plus pepstatinA; 10mg/ml each) for 3 h. The expression level of FLAG-Tatwas revealed byWestern
blotting using anti-FLAG Ab. Levels of expression were quantified by densitometry and normalized to GAPDH expression levels. Data are representative of at
least eight independent experiments for FLAG-Tat. (C)HEK cells were transfectedwith plasmids expressing Flag-Tat, FLAG-Nef, Flag-Vif, orGag. After 24 h, the
transfected cells were either left untreated or treated with 2 mM torin for 3 h. The expression level of the FLAG-tagged proteins or Gag was revealed by Western
blotting using anti-FLAG or anti-p24Gag Ab, respectively. Levels of expression were quantified by densitometry and normalized to GAPDH expression levels.
Data are representative of at least three independent experiments. (D) Chronically infectedMOLT-X4 cells were either left untreated or treated for 3 hwith 2mM
torin 1 in the presence or absence of AP. Cell lysates were then subjected to immunoblotting with anti-Tat Ab and anti-GAPDH Ab as a loading control. Tat
expression levels were quantified by densitometry and normalized to GAPDH protein levels. Data are representative of at least three independent experiments.
(E)HEK cells, previously transfectedwith unspecific (siCT) orATG7-specific (siAtg7) siRNA,were transfectedwith the FLAG-Tat vector for 24 h. Cells were then
either left untreated or treated with 2 mM torin 1 for 3 h before lysis. Cell lysates were immunoblotted with anti-Atg7 Ab, anti-FLAG Ab, or anti-GAPDH Ab as
a loading control. Expression levels of Atg7 (left panels) and Tat (right panels) were quantified by densitometry and normalized to GAPDH protein levels. Data
are representative of at least three independent experiments. (F) HEK cells were transfected with a p62-specific siRNA (sip62) or control siRNA (siCT) and then
transfected with the plasmid expressing FLAG-Tat. The following day, cells were lysed, and p62 and Tat levels were assessed in lysates byWestern blotting using
Abs against p62 and FLAG. Sample loadingwas controlled by immunoblotting with anti-GAPDHAb. Expression levels of p62 (left panels) and Tat (right panels)
were quantified by densitometry and normalized to GAPDH protein levels. Data are representative of four independent experiments. AU, arbitrary units. *, P ,
0.05; ***, P , 0.001.
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this process. We thus analyzed the interaction between Tat and
mutated forms of p62 in which the UBA (GST-p62DUBA) or the
PB1 (GST-p62DPB1) domain was deleted. As shown in Fig. 3B
(lanes 3 and 4), Tat still interacted with these two p62 mutants,
indicating that ubiquitinationmight not influence the interaction
between p62 and Tat in vitro. In accordance with this result, Tat
mutants on known ubiquitinated lysines, previously reported to
regulate Tat activity and stability (K71 and K50/51, respectively)
(36, 42, 43) are still degraded upon induction of autophagy by
torin 1 (Fig. 3C).
Autophagy is induced by HIV-1 envelope glycoproteins
(Env) at the very first steps of HIV-1 infection. To further deci-
pher whether Tat degradation by autophagy could be relevant in
vivo, we analyzed its occurrence in the context of HIV-1 infection.
Indeed, we already demonstrated that autophagy is induced in
uninfected bystander CD41 T lymphocytes after 48 h of coculture
with Env-expressing cells (31). We extended this finding with ex-
periments showing that the fusogenic function of gp41 is respon-
sible for the observed Env-induced autophagy (30). Given that the
gp41-mediated fusion process is an early HIV-1 entry event, we
investigated whether autophagy could be induced very rapidly
after contact of Env with its receptors on target cells before pro-
ductive infection. To this aim,HEK cells expressingHIV receptors
(HEK/CD4/CXCR4) and transfected with a plasmid expressing
GFP-LC3 were cocultured with chronically infected T cells
(MOLT-X4) or with uninfected T cells (MOLT) as a negative con-
trol. The level of autophagy and the percentage of infected cells
were analyzed at different time points of coculture. As shown in
Fig. 4A, autophagy was rapidly induced in read-out cells upon
coculture with MOLT-X4, with a peak around 4 h corresponding
to the early phase of HIV-1 infection (19). Autophagy was then
negatively regulated and finally completely inhibited after 24 h of
coculture, a step corresponding to the late phases of HIV-1 infec-
tion. Importantly, induction of autophagy is inversely correlated
with the level of infection. Of note, the same pattern was obtained
when GFP-LC3-transfected cells were challenged with cell-free
HIV-1 (data not shown). We next analyzed whether the viral en-
velope was contributing to this early autophagy induction during
early events of HIV-1 infection of CD41 T cells. Primary CD41 T
cells, expressing GFP-LC3, were cocultured with effector cells sta-
bly expressing Env, or not, at their surface (HEK.Env orHEK cells,
respectively). As shown in Fig. 4B, Env alone was able to rapidly
and significantly induce autophagy in target cells. To confirm and
reinforce these data, we took advantage of another autophagy
read-out by analyzing the phenotype of primary CD41 T cells by
transmission electron microscopy upon 4 h of coculture with
HEK cells stably expressing Env or not. We detected the appear-
ance of numerous autophagic vacuoles in the cytoplasm of target
CD41 T cells only in the presence of Env (Fig. 4C). Thus, Env is
able to induce autophagy in target cells upon early contact with
FIG 3 p62-dependent interaction of Tat with LC3. (A) HEK cells were cotransfected with the FLAG-Tat vector and plasmids expressing either GST, GST-LC3,
GST-LC3 F52A, GST-p62, or GST-p62DLIR, a indicated. At 24 h posttransfection, cells were lysed, and lysates subjected to GST pulldown before immunoblot-
ting with anti-FLAG Ab and anti-GST Ab. In each case, a fraction of lysates was preserved and used as an input control and immunoblotted with the anti-FLAG
Ab. (B) HEK cells were cotransfected with plasmids expressing FLAG-Tat and either GST alone, GST-p62, GST-p62DUBA, or GST-p62DPB1 before GST
pulldown. Results are representative of at least three independent experiments. (C)HEKcells transfectedwith plasmids expressingwild-type FLAG-Tat (TatWT)
ormutated forms of Tat (Tat K71R or Tat K50/51A) were either left untreated or treated or with 2 mM torin 1 for 3 h. Lysates obtained from each condition were
used to analyze the expression levels of Tat and GAPDH as previously described. FLAG-Tat levels were quantified by densitometry upon normalization with
GAPDH expression levels in the corresponding samples. AU, arbitrary units.
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infected cells. It is interesting that, as shown for Env-mediated
autophagy in longer kinetics of coculture (30), this early au-
tophagy inductionwas dependent on the gp41 fusogenic function.
Indeed, the addition of T20 to the coculture, a gp41-mediated
fusion peptide inhibitor, completely abolished the Env-induced
autophagy (Fig. 4D).
We then analyzed whether later steps of autophagy could be
induced or blocked when cellular lysosomal proteases were inhib-
ited by AP. As evidenced in Fig. 4E, the increased level of LC3-II
obtained upon 4 h of contact with Env-expressing HEK cells was
further enhanced in lysates from cells also pretreated with AP,
confirming that the induced autophagy flux was not blocked dur-
ing the early time points of contact between the viral envelope and
CD41 T cells.
To confirm that Tat could be a selective target for autophagic
degradation in the context of productive infection, we analyzed its
expression levels upon Env-induced autophagy during HIV-1 in-
fection. For this purpose, we transfected a plasmid expressing
FLAG-Tat in HEK/CD4/CXCR4 cells and cocultured these cells
with MOLT-X4 cells for 4 h, a time previously shown to corre-
spond to the peak of Env-mediated autophagy induction, or 48 h,
a time for which autophagy was seemingly inhibited (Fig. 4A). As
expected, the level of LC3-II was increased up to 70% after 4 h of
coculture while being decreased by 40% upon 48 h of coculture
with MOLT-X4 cells, strongly supporting an early induction of
autophagy followed by its blockade during HIV-1 infection. Re-
markably, Tat expression levels were inversely correlated to those
of LC3-II, meaning that Tat is depleted when autophagy is in-
duced, while this effect was not observed under conditions where
autophagy is inhibited by the virus (Fig. 4F).
Env-induced autophagy triggers Tat degradation and conse-
quently represses HIV-1 LTR activation. In order to assess the
contribution of Env-mediated autophagy induction in Tat degra-
dation, we transfected a plasmid expressing FLAG-Tat in HEK/
CD4/CXCR4 cells and treated these cells with the autophagy
initiation inhibitor 3-methyladenine (3-MA) before coculture for
4 h with uninfected or chronically HIV-infected T cells. As shown
in Fig. 5A, Tat levels markedly decreased upon coculture with
FIG 4 Autophagy is induced at early steps of HIV-1 infection. (A) HEK/CD4/CXCR4 cells, previously transfected with a plasmid expressing GFP-LC3, were
cocultured with either MOLT cells (CT, negative control) or chronically infected MOLT-X4 cells (HIV) for the indicated times. The number of autophagic
HEK/CD4/CXCR4 cells was counted by three different experimenters, and the result is themean of three independent experiments. The percentage of autophagic
cells obtained after coculture with MOLT-X4 cells was normalized with the percentage of autophagic cells obtained after coculture with MOLT cells. A
representative pattern of GFP-LC3 puncta inHEK/CD4/CXCR4 cells upon 4 h of coculture withMOLT-X4 cells is presented on the left-hand side and compared
to the fluorescence pattern obtained upon 4 h of coculture with control MOLT cells. In parallel, the percentage of HIV-infected cells was quantified by flow
cytometry using the anti-p24Ab. (B)HumanprimaryCD41 T cells were transfectedwith a plasmid expressingGFP-LC3 and coculturedwithHEK cells (negative
control) or Env-transfected HEK cells for 2 h or 4 h. Quantification was performed as described above, and the results are presented as mean fold value of each
condition from three independent experiments. A representative pattern of GFP-LC3 puncta in primary CD41 T cells upon 4 h of coculture with HEK-Env cells
is presented and compared to the fluorescence pattern obtained upon 4 h of coculture with control HEK cells. (C)Human primary CD41 T cells were cocultured
with HEK cells expressing Env, or not, for 4 h, and autophagic vacuoles were observed by transmission electron microscopy. The percentage of autophagic cells
is presented. (D)HumanprimaryCD41 T cells were coculturedwithHEK cells expressing Env, or not, for 4 h in the presence or absence of AP. CD41 T cells were
harvested, and lysates were immunoblotted with anti-LC3 Ab and anti-GAPDH Ab as a loading control. LC3-II levels were quantified by densitometry and
normalized with GAPDH expression levels. (E) HEK/CD4/CXCR4 cells were transfected with the FLAG-Tat vector and then cocultured with MOLT cells
(negative control) or withMOLT-X4 cells for 4 h and 48 h. Suspension cells were removed by washing, and autophagy induction was monitored in the lysates of
target cells upon immunoblotting with anti-LC3 Ab (left panel). Tat levels were assessed with the anti-FLAG Ab (right panel), while sample loading was
controlled with the anti-GAPDH Ab for each condition. LC3-II and Tat levels were quantified by densitometry upon normalization with GAPDH expression
levels in the corresponding samples. *, P , 0.05; **, P , 0.01; ***, P , 0.001.
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MOLT-X4 cells, while they were fully rescued in the presence of
3-MA. This result confirms that Env-mediated autophagy flux
induction is responsible for Tat degradation. We reproduced the
experiments using 8.E5 cells as donor cells. These CD41 T cells are
productively infected, thus expressing Env at the surface, but be-
cause they do not express the reverse transcriptase, they do not
produce infectious viral particles. With this model, the Env-me-
diated autophagy induction was even more pronounced, as evi-
denced by the increased and sustained Tat degradation observed
in target cells (Fig. 5B).
While viral challenge could rapidly and transiently induce au-
tophagy, productive infection appeared to block this defense
mechanism, thus potentially protecting the viral transactivator
Tat from degradation. Interestingly, Tat can exert multiple effects
on bystander cells when secreted from productively infected cells.
For instance, secretedTatwas reported to transactivate the expres-
sion of genes under the control of the HIV LTR in bystander cells.
To examine whether incoming Tat could be degraded by au-
tophagy, we used HeLa cells expressing CD4 and CXCR4 together
with b-galactosidase under the control of the HIV LTR promoter
(MAGIC5B cells) (44). MAGIC5B cells were cocultured for 4 h
and 8 h with MOLT-X4 cells in the presence or absence of 3-MA,
and b-galactosidase activity was measured. Enzymatic activity
could be detected in reporter target cells, supporting the bystander
effect of secreted Tat. Transactivation was significantly increased
in the presence of 3-MA, strongly suggesting that autophagy con-
trols Tat-mediated transactivation of the HIV LTR (Fig. 5C). Be-
cause 3-MA could have some side effects possibly affecting Tat
secretion from infected cells, we aimed at confirming these results
by directly downregulating the expression of essential ATG pro-
teins in target cells. Therefore, MAGIC5B cells were transfected
with siRNA directed against beclin 1 or Atg7 or unrelated siRNA
before coculture with MOLT-X4 cells. As expected, the level of
b-galactosidase activity was increased at both time points of co-
culture when beclin 1 or Atg7 expression was silenced (Fig. 5D).
Inversely, autophagy induction should inhibit HIV LTR transac-
tivation due to Tat degradation (Fig. 2). Indeed, when MAGIC5B
cells were cocultured withMOLT-X4 cells in the presence of torin
1, we observed a significant decrease of b-galactosidase activity,
inversely correlated with the increased enzymatic activity ob-
FIG 5 Autophagy-mediated Tat degradation inhibits HIV-1 LTR activation and viral replication. (A) HEK/CD4/CXCR4 cells transfected with the FLAG-Tat
vector were cocultured with uninfected (MOLT) or chronically HIV-1-infected cells (MOLT-X4) cells for 4 h in the presence or absence of 10 mM 3-MA. Tat
expression was monitored by Western blotting using the anti-FLAG Ab and quantified upon normalization with GAPDH levels. (B) HEK/CD4/CXCR4 cells,
transfected as above, were cocultured for 4 h with effector control cells (Env negative) or cells expressing HIV-1 envelope (8.E5 cells). Tat detection and
quantification were done as previously described. (C) MAGIC5B cells were cocultured with MOLT-X4 cells for 4 h or 8 h in the presence or absence of 3-MA.
After cell lysis, b-galactosidase activity was quantified by luminescence and normalized to the condition in the absence of 3-MA for each time of coculture. Data
represent the means 6 standard errors of at least three independent experiments. (D) MAGIC5B cells were transfected with control (CT) or beclin 1 (Bec1)- or
Atg7-specific siRNA for 16 h. Transfected cells were then cocultured withMOLT-X4 cells for 4 h. The cells were washed, harvested, and then lysed. A fraction of
lysates was kept to control beclin 1, ATG7, and GAPDH levels by immunoblotting (left panels) while remaining lysates were used to measure b-galactosidase
activity, normalized to the activity obtained from cells transfected with CT siRNAs for each time point. Data are means 6 standard errors of four independent
experiments. (E) MAGIC5B cells cocultured with MOLT-X4 cells were incubated or not with 2 mM torin 1 for 16 h in the presence or absence of AP. Fold
induction of b-galactosidase activity was calculated as the enzymatic activity obtained in treated cells compared to that in untreated cells. Data are representative
of at least three independent experiments. (F) MAGIC5B cells were incubated for 48 h with 200 nM recombinant wild-type Tat (Tat), mutant Tat (W11Y), or
medium alone (Ct) before b-galactosidase activity was assayed. (G) MAGIC5B cells, treated as in described for panel D, were incubated for 48 h with 200 nM
recombinant Tat or W11Y. A fraction of lysates was kept to for beclin 1 and GAPDH levels by immunoblotting while remaining lysates were used to measure
b-galactosidase activity. Data are representative of at least five independent experiments. RLU, relative light units. *, P , 0.05; **, P , 0.01; ***, P , 0.001.
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tained upon autophagy flux blockade with AP (Fig. 5E). Hence,
the effect of drug-mediated autophagy induction on transactiva-
tion by Tat appeared to be sustained, as evidenced by the de-
creased transactivation upon 16 h of coculture (Fig. 5E). These
data thus show that the autophagy pathway can be a major regu-
lator of Tat-mediated transactivation and viral replication. This
conclusion is valid whether Tat is produced intracellularly (i.e., by
infected cells) or delivered from the outside (i.e., endocytosed).
Indeed, to confirm that the detected viral promoter transacti-
vation was exclusively Tat dependent and controlled by au-
tophagy, we took advantage of a previously described Tat mutant
that lacks its single tryptophan residue (Tat-W11Y). This mutant
retains transactivation activity but is unable to enter bystander
cells (35) (Fig. 5F). MAGIC5B cells were transfected with a beclin
1-specific siRNAor a control siRNA and then treatedwith 200 nM
recombinant wild-type Tat (Tat-WT) or Tat-W11Y, and b-galac-
tosidase activity was measured after 48 h. We observed that, in
contrast to cells treated with Tat-WT, transactivation was not sig-
nificant when Tat-W11Y was used (Fig. 5G). These results con-
firm that transactivation by incoming Tat is targeted by selective
autophagy.
DISCUSSION
HIV-1, like other viruses, has to deal with cellular defenses in
order to replicate efficiently. Although several cellular HIV-1 re-
striction factors have been identified, most of themwere shown to
be affected by viral countermeasures (45). We previously demon-
strated that HIV-1 Env induces autophagy in uninfected CD41 T
lymphocytes via the fusogenic function of gp41, leading to their
apoptotic cell death (30, 31). In this study, we demonstrate that
induction of autophagy is readily detectable early after viral chal-
lenge in an Env-dependent manner, while being compromised at
later times. Autophagic activity is inversely correlated with HIV-1
production. We further provide evidence that autophagy, when
pharmacologically induced in productively infected CD41 T cells,
leads to a significant decrease in viral production, thus identifying
this cellular pathway as an HIV-1 restriction mechanism. This
observation led us to decipher the molecular mechanism of the
autophagy-mediated antiviral effect. A two-hybrid screen re-
vealed a strong and specific interaction between p62 (also called
SQSTM1), an autophagy receptor, and the viral transactivator
Tat.We first confirmed the interaction between the proteins at the
cellular level in pulldown assays and confirmed that Tat expres-
sion levels were modulated in cells upon autophagy activation or
inhibition. We then demonstrated that Tat expression was signif-
icantly increased in p62-deficient cells, suggesting that p62 could
be a mediator of Tat degradation by selective autophagy. We
therefore analyzed the domains of p62 possibly involved in the
interaction with Tat. Surprisingly, the interaction between Tat
and p62 did not rely on a functional UBA domain of p62, suggest-
ing that ubiquitination would not regulate p62-mediated Tat deg-
radation, in contrast to the general paradigm reported for other
substrates (46). Consistently, Tat mutations at the level of lysines,
which were previously shown to regulate Tat stability and activity,
did not prevent its degradation upon autophagy induction. Al-
though we cannot exclude modification of other residues or the
involvement of unidentified cellular proteins belonging to the
complex Tat/p62, our data represent the first demonstration of
selective autophagic degradation of a viral transactivator. Indeed,
in a context of viral infection, a selective p62-mediated degrada-
tion has been demonstrated only for two structural viral proteins,
the capsid protein of the chikungunya virus (CHIKV) and the
capsid protein of the Sindbis virus (SIN) (4, 47). In the case of
CHIKV, p62 binds to ubiquitinated capsid and targets it to au-
tophagic degradation, while in the case of the SIN, and reminis-
cent of our data for Tat, the interaction between p62 and the SIN
capsid does not require the p62 UBA domain, highlighting a po-
tential original mechanism by which p62 recognizes autophagic
substrates. As p62 could frequently interact with viral proteins
(48), it would be interesting to decipher themolecularmechanism
behind this ubiquitin-independent p62-mediated autophagic
degradation, with a particular emphasis on the identification of
other putative cellular partners linking p62 to its substrates. One
potential candidate is the histone deacetylase HDAC6, whose
deacetylase activity was shown to be regulated upon interaction
with p62 (49). Furthermore, HDAC6 was also reported to
deacetylate Tat, leading to a decrease in Tat transactivation activ-
ity (50).
Although cellular factors are involved in HIV-1 transcription,
Tat is absolutely required for HIV-1 replication since it is needed
for the elongation of viral transcripts (20). Tat is thus a perfect
target to shut down viral production. Interestingly, Tat was shown
to be actively secreted from infected cells and captured by several
cell types (21, 42). Our results suggest that incoming Tat is also a
target for autophagic degradation following internalization by by-
stander cells. The consequences of this degradation on the differ-
ent known effects of Tat and, in particular, on the homeostasis of
target cells warrant further investigation.
We discovered that autophagy is induced by HIV-1 Env at the
very first steps of infection. This Env-induced autophagy is time
regulated and initially triggers the degradation of any incoming
Tat, avoiding the death of the target cells long enough to allow the
virus to initiate its replication. If productive infection of the target
cells proceeds, the virus blocks autophagy, and Tat, thereby pro-
tected from degradation, can fulfill its transcriptional role, en-
abling robust viral production.
Intracellular Tat concentration is tightly regulated. Indeed, we
demonstrated here that Tat can be degraded by basal constitutive
autophagy and upon Env-induced autophagy. Tat was also re-
ported to inhibit the autophagy process in uninfected cells (33,
34), underlining the complex relationship between autophagy and
this viral protein. This also seems to be the case for another retro-
viral transactivator, the human T-cell leukemia virus type 1
(HTLV-1) Tax protein. Indeed, it has been demonstrated that Tax
is a substrate for autophagy degradation, but the underlying
mechanism is still unknown (51). They also demonstrated that
Tax is able to block the degradative phases of autophagy, suggest-
ing that this viral protein could control its own stability and turn-
over (51).
Highly active antiretroviral therapy (HAART) can efficiently
block viral replication and reduce the levels of circulating virus
below the detection limit. Despite its efficacy, the virus is not erad-
icated due to the establishment of latent but replication-compe-
tent proviruses in reservoir cells probably located in peripheral
blood and tissues. Viral latency is characterized by HIV-1 LTR
transcriptional repression, and, interestingly, a hallmark of this
process is the low level of Tat. Thus, specific degradation of Tat by
autophagy could adversely contribute to the establishment of
HIV-1 latency, which should be taken into account in the context
of future antiviral strategies.
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Since Tat is absolutely required for viral transcription, many
therapeutic strategies targeting this viral protein have been con-
sidered, such as Tat antagonists (52), dominant negative Tat (53,
54), Tat-inhibitory peptides (55–58), or siRNAs against Tat (59–
61). However, none of these strategies has been successful to date.
The autophagy-mediated degradation of Tat presented here could
represent a new way to target this viral protein in infected cells,
blocking viral transcription and thus viral replication. Indeed,
while HAART acts directly on viral enzymatic proteins, the in-
duced degradation of Tat by autophagy could represent a new
strategy based on a cellular response. Interestingly, some siroli-
mus-derived compounds (rapamycin and rapamune), which are
strong inducers of autophagy and already used in therapeutics,
were shown to possess anti-HIV-1 properties (62). Recently,
Campbell and Spector demonstrated that vitaminD3 inhibitsHIV
replication through induction of autophagy (63). It would be in-
teresting, therefore, to examine the autophagy-induced degrada-
tion of Tat in these contexts and its possible outcome on inhibi-
tion of HIV replication.
The results obtained in our study provide new evidence of the
antiviral action of autophagy and highlight why the viruses have
evolved strategies to block this process.
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To eat or not to eat: the intricate relationship between 
autophagy and HIV-1 
ABSTRACT 
A consensus is now growing on the fact that 
autophagy can behave as an antiviral mechanism 
against incoming pathogens. Therefore, some 
pathogens have evolved to counteract or benefit 
from the cellular autophagy machinery. The 
Human Immunodeficiency Virus (HIV), like 
many viruses, manipulates autophagy to favor its 
replication. In particular, HIV-1 envelope (Env) 
plays an important role in modulating autophagy 
in CD4+ T cells and phagocytic cells. Env-
mediated autophagy is a cell-type dependent 
mechanism activated in bystander CD4+ T cells 
but totally inhibited during their productive 
infection. In both infected myeloid dendritic 
cells and macrophages, the autophagy flux is 
progressively shut-down. The modulation of 
autophagy by HIV in these cell types could be 
responsible for the onset of HIV-mediated 
immunopathogenesis and contribute to viral 
spread. The former effect is responsible for 
apoptosis of bystander CD4+ T cells and the latter 
correlates with a viral escape strategy favoring 
viral replication and transmission by counteracting
  
autophagy-mediated antiviral immunity. Furthermore, 
HIV-1 can infect different cell types of the central 
nervous system such as the microglia and, in a 
restrictive manner, the astrocytes and the neural 
precursors for which infection has also been 
correlated with modulation of autophagy. The 
aim of this review is to provide an overview on 
the intricate and conflicting relationships that 
intimately link HIV-1 and autophagy in these 
different cell types. 
 
KEYWORDS: HIV-1, autophagy, infection 
 
1. INTRODUCTION 
Despite more than 30 years of intense basic and 
clinical studies on HIV infection, the scientific 
challenge remains, since 35 million people are 
still living with HIV worldwide (data from 
UNAIDS, 2013). Although tremendous success 
has been achieved to date in the treatment 
(HAART, highly active antiretroviral therapy), no 
cure has yet been found, mainly due to viral 
resistance and persistence of viral cell reservoirs. 
It has progressively become clear that HIV 
infection is highly complex, explaining the  
failure to cure this disease. HIV infection induces 
the early establishment of a chronic immune 
activation that plays a crucial role in HIV 
pathogenesis by triggering progressively the 
exhaustion and collapse of the whole immune 
system ([1] for review). Moreover, this infection 
triggers the progressive depletion of CD4
+ T cells, 
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In this review, we detail the past and recent 
research aimed at investigating the complex 
interplay between the cellular autophagy pathway 
and HIV infection. 
1.1. CD4
+
 T cells 
CD4+ T lymphocytes represent the main target 
cell population for HIV-1 infection [12, 13] and 
their progressive destruction is the hallmark of its 
associated disease [14]. CD4
+ T cell activation is 
thought to be a major factor in facilitating HIV-1 
infection of these cells [15, 16].  
CD4+ T lymphocytes constitute a highly 
heterogeneous population divided by functional 
and phenotypic differences, and their activation, 
immune status and localization directly influence 
their susceptibility to HIV-1 infection and the 
consequent viral-mediated immunopathogenesis. 
They can be broadly divided into naive and 
memory subsets, and both subsets are composed 
of many subpopulations. Upon microbial infection, 
naive CD4
+ T cells are activated after their 
interaction with DC carrying and presenting 
specific pathogen-derived antigens. Depending on 
the cytokine environment and the source of 
antigens, the antigen-specific CD4
+ T lymphocytes 
can then rapidly proliferate and differentiate into 
several cell subsets with highly specialized 
immunologic functions, such as Th1, Th2, Th17 
and regulatory T cells [17]. Quiescent naive and 
resting CD4
+ T cells were reported to be relatively 
resistant to HIV-1 infection [16, 18] possibly 
due to the low metabolic rate and antiviral 
mechanisms present in these cells [19, 20]. On the 
other hand, non-quiescent memory CD4
+ T cells 
were shown to support active HIV-1 replication 
with differences in their half-life, mainly 
depending on their maturation level [21, 22]. 
Although the majority of these cells die rapidly, a 
small proportion can undergo a transition toward a 
resting state [23]. Nevertheless, rapidly after acute 
infection, viral dissemination to lymphoid tissues 
and exponential HIV-1 replication throughout the 
lymphatic system lead to the depletion of most 
mucosal CD4
+ memory T cells [24-28] and to the 
subsequent establishment of reservoir cells in 
mucosa-associated lymphoid tissues (MALT) 
[29-31]. Importantly, this major effect was observed 
in non-human primate models [32-34] as well as
  
 
leading to increased susceptibility to opportunistic 
infections [2-4]. A residual chronic immune 
activation persists even in HIV-infected patients 
in whom viral replication is successfully inhibited 
by HAART, and the extent of this residual 
immune activation is associated with CD4+ T cell 
loss [5]. However, a causal link between chronic 
immune activation and CD4+ T cell loss has not 
yet been formally demonstrated. 
During sexual transmission, viruses cross 
epithelia and encounter their target cells, mainly 
CD4+ T cells, dendritic cell (DC) subsets and 
macrophages. CD4+ T cells, macrophages and 
only a small proportion of DC are productively 
infected. Most of the DC capture the virus via cell 
surface C-type lectin receptors, such as DC-SIGN, 
and migrate toward lymph nodes or other 
secondary lymphoid organs, where they can 
transmit HIV-1 to CD4+ T cells [6]. HIV also 
crosses the blood-brain barrier (BBB) and enters 
the central nervous system (CNS) early after the 
initial systemic infection, leading to cognitive 
deficits known as HAND (HIV-associated 
neurocognitive disorders) that appear in up to 
50% of HIV patients in the later stages of 
infection [7]. 
In most instances, to enter and productively infect 
a target cell, HIV must bind to CD4 and specific 
co-receptors, like CCR5 or CXCR4, belonging to 
the chemokine receptor family and related to viral 
tropism (For a recent review see [8]). Co-receptor 
usage is correlated, at least in part, with the 
different phases of the disease. R5-tropic viruses, 
which utilize CCR5, are predominantly represented 
during the early stages of HIV-1 infection. In 
infected patients, the emergence of X4-tropic 
variants, which use CXCR4, is almost invariably 
associated with faster decline of circulating CD4+ 
T cells, accelerated disease progression and 
poor prognosis for survival [9, 10]. However, the 
presence of X4 viruses is not an obligatory 
prerequisite for disease progression and a 
significant proportion of individuals who progress 
to AIDS exclusively harbors R5 variants. The 
selective and dominant transmission of R5-tropic 
viruses is not fully understood, but it may depend 
on the superimposition of multiple imperfect 
gatekeepers that restrict HIV-1 X4 transmission at 
different steps of the infection process [11]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV-1 and autophagy 
During HIV-1 infection, many different 
mechanisms seem responsible for the death of 
infected and uninfected CD4+ T cells. However, 
during the prolonged, asymptomatic phase of the 
disease, the death of uninfected bystander CD4+ 
T cells is thought to be the main cause of CD4+ 
T cell depletion. It is now well admitted that the 
gp41-mediated fusion process triggers activation 
of the intrinsic pathway of apoptosis, with 
activation of the caspases 9 and 3 [53-56]. 
Recently, abortive HIV-1 infection occurring in 
the vast majority of bystander quiescent CD4+ 
T cells, was shown to be responsible for an 
inflammatory form of cell death called pyroptosis, 
with activation of caspase 1 and release of 
inflammatory cytokines [57, 58] upon viral DNA 
sensing by the interferon- -inducible protein 16 
(IFI16) [59, 60]. 
1.2. Macrophages 
Macrophages are terminally differentiated, non-
dividing cells, derived from circulating monocytes. 
They are present in most tissues with different 
denominations, e.g. microglia in the brain, 
alveolar macrophages in the lung, or Kupffer cells 
in the liver. Although circulating monocytes are 
relatively resistant to HIV-1 infection, macrophages 
can be productively infected and play important 
roles in the different phases of HIV-1 infection. In 
addition, they have been reported to be resistant to 
HIV-1-induced cytopathic effects, thus representing 
a significant viral reservoir population which can 
survive for a long time [61]. 
First, they act as antigen presenting cells (APC), 
leading to the presentation of HIV-1-derived 
peptides via major histocompatibility complex 
class II (MHC-II) and MHC class I (MHC-I) 
molecules to CD4+ and CD8+ T cells, respectively 
(for review see [62]). HIV-1-infected macrophages 
can also attract CD4+ T cells through secretion of 
cytokines, thus favoring HIV-1 transfer upon cell-
to-cell contacts or directly influencing viral spread 
by migrating and infiltrating other organs, 
including the brain. 
Like CD4+ T cells, macrophages express the main 
HIV receptors and co-receptors and can thus be 
infected by X4-tropic or R5-tropic viruses. However, 
they are more frequently and efficiently infected 
by HIV-1 R5 strains, which exploit low levels of
in humanized mice models of HIV infection 
[35, 36]. Therefore, resting memory CD4+ T cells 
could represent a significant viral reservoir 
seemingly responsible for the failure to eradicate 
HIV infection upon antiviral therapies [24, 37-40]. 
Interestingly, an immature memory T cell 
population with stem cell-like properties called 
CD4+ T memory stem cells (TSCM cells), the most 
long-lasting central memory CD4+ T cells, were 
reported to harbor high levels of HIV-1 DNA, 
thus potentially providing a viral reservoir over 
time [41].  
HIV-1 entry in CD4+ T cells relies mainly on a 
receptor-dependent process, leading to the fusion 
of the target cell membrane with the viral or the 
HIV-infected cell membrane [42]. More precisely, 
the HIV-1 envelope (Env), expressed at the 
surface of free virions or infected cells and 
composed of the glycoproteins gp120 and gp41, 
binds to CD4. This interaction triggers structural 
changes leading to increased exposure of gp120 
regions (including the V3 loop) that can bind to 
the co-receptors, mainly CCR5 or CXCR4 [43]. 
Finally, interaction of gp120 with the co-receptor 
induces a structural rearrangement of the trans-
membrane Env-subunit gp41 and insertion of the 
fusion domain at the N-terminus of gp41 into the 
target cell membrane. At this stage, gp41 adopts 
a trimeric extended pre-hairpin intermediate 
conformation before the formation of a stable six-
helix bundle structure, thus facilitating virus/cell-
to-cell fusion. Although occurring with cell-free 
viruses, the efficiency of HIV-1 infection is 
higher when the virus is delivered through cell-to-
cell contacts upon formation of the so-called 
virological synapses (VS) [44-49]. Indeed, DCs 
and macrophages, the first cells encountering 
HIV-1, efficiently transmit HIV-1 to CD4+ T cells 
through these synaptic structures in which viral 
proteins and cellular receptors were shown to be 
polarized. This way of spread also occurs between 
HIV-1-infected and uninfected CD4+ T cells [44, 
50]. Notably, cell-to-cell fusion can lead to the 
formation of giant, multinucleated cells [3] called 
syncytia, which could precede apoptotic events 
in vitro [51]. In vivo, syncytia could generate 
long membrane tethers, thus facilitating viral 
dissemination [52].   
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compartments required to maintain a viral 
reservoir or do they represent a potential source 
for a rapid transfer of viral infection? The answer 
to this will require further investigation but an 
interesting recent report demonstrated that 
targeting these VCCs with antibodies directed 
against CD36 could block HIV-1 release and viral 
transfer toward CD4+ T cells [83]. 
1.3. Dendritic cells 
The two main DC subsets in the blood can be 
identified based on specific receptor expression. 
The most represented subset, although constituting 
only 0.5% of the whole peripheral blood 
mononuclear cells, belongs to the conventional or 
myeloid DC (cDC or myDC) and is usually 
characterized by the specific expression of CD1c 
(BDCA1) or CD141 (BDCA3) in parallel to 
myeloid markers like CD11c, CD13 and CD33. 
These cells migrate rapidly to inflamed tissues 
and secrete high levels of cytokines (like IL-6, 
IL-12, IL-15) and chemokines (CCL17, CCL22 
for example) in response to microbial stimuli. 
Plasmacytoid DC (pDC) represent a rarer subset 
of cells (0.1-0.2% of the whole PBMC) mainly 
characterized by a plasma cell morphology and 
the specific expression of CD303 (BDCA2), 
CD304 (BDCA4/Neuropilin-1) and CD123 (IL-3 
Receptor alpha-chain). Although pDC share some 
common markers, they are thought to be from 
lymphoid origin and were previously coined as 
interferon (IFN)-producing cells (IPC) due to their 
unique ability to rapidly secrete massive amounts 
of type 1 IFN following viral stimulation (for 
review see [84]), thus placing these cells at the 
forefront of innate immune response initiation.  
Environmentally exposed surfaces of the body are 
privileged sites for other unique DC subsets. The 
human epidermal and mucosa upper layers are 
homogeneously populated with Langerhans cells 
(LC) mainly characterized by the specific 
expression of the C-type lectin receptor (CLR) 
CD207 (Langerin) whereas the subjacent layers 
present various dermal DC subsets (dDC), some 
of them expressing CD209 (DC-SIGN). 
Although all these subsets could differ in 
phenotype and functions, one of their hallmarks is 
their propensity to regulate innate and adaptive 
immunity. Indeed, most of these subsets express a
CD4 and/or CCR5 to enter macrophages [63, 64]. 
While macrophages express HIV-1 receptors, 
allowing viral entry via gp41-mediated plasma 
membrane fusion, the low level of CD4 seems 
to favor virus uptake through endocytosis, 
presumably due to the barrier formed by the actin 
cortex and the presence of intrinsic antiviral 
factors [65]. The favored model for productive 
HIV-1 entry in these cells would rely on 
endocytosis via lipid microdomains of the plasma 
membrane containing CD4 and CCR5, and the 
efficient gp41-dependent fusion after endocytosis, 
therefore allowing viruses to escape degradation 
[66-68]. This complex and yet unclear pathway 
was called “pathway of HIV endocytic entry in 
macrophages” (PHEEM) [66, 67]. Alternatively, 
productive infection of macrophages may occur 
after endocytosis of HIV-1 through a CD4-
independent mechanism, although the inherent 
mechanisms are not yet fully elucidated and most 
of the incoming virions are mainly degraded by 
this way [69]. 
Additional cellular membrane receptors were 
described to support HIV-1 entry in macrophages, 
including syndecan, a heparin sulfate proteoglycan 
[70, 71]; gp340, a cysteine-rich scavenger receptor 
[72]; the macrophage mannose receptor [73-75]; 
elastase [76]; and -v-integrin [77] supposedly by 
facilitating viral attachment, binding, entry and/or 
fusion. Another potential membrane ligand of 
HIV-1 is annexin II, which is expressed on the 
membrane of macrophages, but not of T cells. 
Annexin II, which binds to phosphatidylserine 
(PS), an anionic phospholipid captured during 
HIV-1 budding, contributes to the early events of 
macrophage HIV-1 infection [78]. Other candidate 
host cell surface proteins that are incorporated in 
HIV-1 membranes and are potentially needed for 
HIV-1 entry might include CD28, CD44, and 
CD62L [79]. 
In infected macrophages, striking observations 
were reported on infectious viruses accumulating 
in cytoplasmic virus-containing compartments 
(VCCs), the nature of which is still debated. 
Although first described as internal compartments 
that possess the characteristics of late endosomes/ 
multivesicular bodies (LEs/MVBs), these VCC 
are not acidified with a fraction of them connected 
to the plasma membrane [80-82]. Are these 
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an efficient productive infection, there are other 
portals for viral entry via binding to other 
receptors, some of them being specifically 
expressed in DC subsets. Indeed, carbohydrate-
binding receptors are widely expressed on all DC 
subsets and were reported to represent the 
dominant HIV-envelope receptors in myeloid DC 
[111, 112]. Some of these receptors, like CD209 
(DC-SIGN), CD206 (Mannose receptor), CD207 
(Langerin) or CLEC4A (DCIR) belong to the 
C-type lectin receptor (CLR) family and were 
demonstrated to internalize HIV and regulate DC-
mediated viral transmission toward CD4+ T cells 
[112-115]. Interestingly, most of these CLR were 
also reported to contribute to immune responses 
upon pathogen capture and internalization [116-
120]. Outstandingly, targeting antigens to DC via 
these CLR was reproducibly showing enhanced 
humoral and cellular immune responses thus 
rendering this approach attractive for innovative 
prophylactic strategies [118, 121, 122]. However, 
some of these CLR can be used by HIV to escape 
immune recognition and to favor viral spread. For 
instance, upon internalization into DC, some 
virions can escape lysosomal-mediated degradation 
and remain over time in a tetraspanin-rich 
compartment [123], suggested to be a source for 
viral transfer toward CD4+ target T cells. The 
complexity of HIV entry into DC and the inherent 
intracellular viral trafficking require further 
investigation in order to find potential treatments 
able to tackle the early events of HIV infection 
and transmission. 
1.4. Neuronal cells  
The BBB isolates the CNS from the blood stream 
and thus may favor viral escape from immune 
surveillance and persistence for pathogens that 
have the ability to cross this cellular structure. 
HIV can access the CNS soon after the initial 
infection by using cells of the immune system 
such as T cells and macrophages, a process coined 
“trojan horse” [124, 125]. Once in the brain, HIV 
infects and replicates in macrophages and microglial 
cells as well as, in a restrictive manner, in 
astrocytes and neural precursors (NPCs). Following 
this neuronal invasion, and in correlation with the 
viral load, cognitive deficits known as HIV 
associated neurocognitive disorder (HAND) will 
appear in up to 50% of HIV patients [126].  
 
plethora of pathogen recognition receptors (PRR) 
facilitating their antigen sampling activity and 
contributing to their quickness in efficiently 
igniting adapted immune responses.  
There is now increased evidence that mucosal 
DC subtypes, macrophages and CD4+ T cells are 
involved in the early events of HIV transmission 
[85, 86]. Indeed, in non-human primate models of 
simian immunodeficiency virus (SIV) infection, 
while CD4+ T cells would represent the majority 
of infected cells, mucosal DC could be carriers 
of infection and amplify viral transmission rates 
[87-90]. Some reports also evidenced the involvement 
of other DC subsets early after acute infection and 
seemingly contributing to viral spread. In fact, 
pDC and myDC were shown to be recruited to 
infected tissues via the secretion of specific 
chemoattractants like CCL20 or thymic stromal 
lymphopoietin (TSLP), respectively [91, 92]. 
Activation of these DC subsets on site would lead 
to secretion of other chemokines (CCL3, CCL4 
etc.), thus fueling the infected tissues with CD4+ 
viral target cells and also contributing to the onset 
of immunopathogenesis linked to chronic immune 
activation. Indeed, recent reports clearly evidenced 
a systemic redistribution of pDC to mucosal 
tissues of chronically infected macaques [93, 94] 
which could account for the chronic immune 
activation. Accumulation of pDC and myDC was 
also observed in lymphoid tissues of chronically 
HIV-infected patients [95]. 
Although most myeloid DC subsets appeared to 
be refractory to productive HIV infection, these 
cells can readily capture and internalize virions 
via different receptors expressed at the surface. 
All DC subsets express the main HIV receptor 
CD4 and the co-receptors CCR5 and CXCR4, 
although the levels of expression vary depending 
on the subsets [96-99]. It is now becoming clear 
that productive HIV-1 infection of most DC 
subsets is profoundly impeded at a post-entry 
level due to the expression [100, 101] and 
phosphorylation status [102, 103] of the deoxy-
nucleoside triphosphate triphosphohydrolase 
SAMHD1, an important regulator of the 
intracellular dNTP pool [104-106]. DC subsets 
also possess other important antiviral activities 
affecting different steps of the viral replication 
cycle [107-110]. Although not supposed to lead to
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described. Evidence suggests that the BBB 
integrity will be impaired by infected astrocytes 
[139].  
NPCs have the ability to generate neurons and 
glial cells both during development and 
adulthood. Indeed, adult neurogenesis allows, in 
defined regions of the CNS, the generation and 
integration of new neurons, which can modulate 
existing neuronal networks and complex cognitive 
tasks such as learning and memory. Contrary to 
fully differentiated neurons, HIV has been shown 
to infect developing and adult NPCs. These cells 
are also believed to act as a major reservoir for 
HIV [140]. Moreover, infected NPCs have been 
shown to be able to differentiate into astrocytes, 
which still contain viral genomes and therefore 
allow (restrictive) viral replication [141, 142]. 
Here also, viral proteins may have a direct effect 
on NPCs: gp120 is shown to trigger mental 
retardation in rodent models [143] and induces 
quiescence in NPCs [144] and cell cycle arrest 
in adult NPCs [145], whereas Tat is reported 
to affect NPC proliferation and differentiation 
[146, 147].  
To fight invading microorganisms, such as HIV-1, 
the cells have a combination of essential defense 
mechanisms. One of the most ancient and powerful 
mechanisms is autophagy, a dynamic and tightly 
regulated pathway that degrades intracellular 
components upon fusion with lysosomes. 
 
2. Autophagy 
Autophagy is a fundamental and highly regulated 
lysosomal degradation mechanism which is 
dependent on specialized autophagy-related proteins 
(Atgs) [148]. This mechanism plays essential 
physiological roles in survival, homeostasis and 
development. It is also involved in the defense 
against invading intracellular pathogens and acts 
in both innate and adaptive immunity. Autophagy 
can be classified into at least three different types: 
macroautophagy, microautophagy and chaperone-
mediated autophagy (CMA) [149]. Macroautophagy 
is the major lysosomal route for the turnover of 
cytoplasmic constituents, and will be hereafter 
referred to as autophagy. It is characterized by a 
highly dynamic flux initiated with the formation 
of intracellular isolation membranes, called 
phagophores. The origin of the membranes is still
  
Due to the lack of CD4 expression, neurons are 
not direct targets for HIV infection. Nonetheless, 
neurotoxicity is found in HAND patients and is 
associated with lower quality of life and decreased 
lifespan. In the most severe cases, patients 
develop HIV-associated dementia (HAD), which 
is one of the most important complication 
associated with AIDS. In this light, HAD closely 
resembles pathologies such as Alzheimer’s and 
Parkinson’s diseases [127-129]. 
It is commonly accepted that HAND results from 
two intertwined effects due to viral and host 
factors. By infecting cells of the circulating and 
local immune systems, HIV triggers neuro-
inflammation associated with selective neuronal 
apoptosis, mostly through chemokine and cytokine 
release [130, 131]. Moreover, some viral proteins 
such as gp120 and Tat can induce specific signals 
that are associated with neurotoxicity [132-135]. 
Notably, these proteins can directly interact with 
neurons, be internalized and activate signaling 
cascades. 
As delivery of HAART in the CNS can be poorly 
efficient, infected brain cells are often referred 
to as reservoirs for HIV and thus represent 
particularly important therapeutic targets. 
Microglial cells are considered as the equivalent 
of resident macrophages in the brain and represent 
10-15% of glia cells [136]. They are distributed in 
a widespread manner in the brain and spinal cord 
but occupy a defined territory. After activation, 
they can change their morphology, migrate, 
proliferate and phagocyte. They are the main brain 
target for HIV as they represent the main source 
of active HIV infection in the CNS [130, 137]. 
Like macrophages, they can be directly activated 
by HIV infection, or by the interaction of viral 
proteins or host factors released by surrounding 
infected cells. In turn, activated microglia cells 
will secrete host factors such as chemokines, 
cytokines and excitatory amino acids that will 
have key roles in HIV-associated neurotoxicity 
[130, 137, 138]. 
Astrocytes are the most abundant cell type in the 
brain and can be infected by HIV but harbor non-
productive infection. Only a small population of 
astrocytes seems to be infected and the exact 
relevance in HAND mechanisms is still poorly 
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Two unique ubiquitin (Ub)-like conjugation 
systems drive the elongation and closure of the 
phagophore. In the first conjugation system, 
Atg12 is conjugated to Atg5, in a reaction 
mediated by the E1-like enzyme Atg7 and the E2-
like enzyme Atg10 [169]. However, in contrast to 
the conventional ubiquitin conjugation system, no 
specific and exclusive E3-like enzyme has been 
discovered so far. Another autophagy-related 
protein Atg16L1, was demonstrated to interact 
with the Atg12-Atg5 conjugate in order to 
regulate the localization of the protein complex to 
isolation membranes while also specifying the site 
of LC3 lipidation. The second conjugation system 
is quite unusual by the fact that proteins of the 
Atg8 family could be directly conjugated to the 
lipid phosphatidylethanolamine (PE) through a 
mechanism controlled by Atg7 and Atg3, another 
E2-like enzyme [170, 171]. In humans, the Atg8 
family comprises three microtubule-associated 
protein, 1 light chain 3 (LC3A, B and C), one 
gamma-aminobutyrate receptor-associated protein 
(GABARAP) and three GABARAP-like proteins 
(GABARAPL1-3) that can be linked to PE [172]. 
However, only LC3B has been extensively 
studied, and will be hereafter referred to as LC3. 
Interestingly, the Atg12–Atg5 conjugate acts as  
an E3 for the conjugation of LC3 to PE [173]. 
LC3 is synthesized as pro-LC3 and is very rapidly 
processed by the protease Atg4 to expose its C-
terminal glycine [174, 175]. During autophagosome 
formation, this cytosolic, soluble form of LC3 
called LC3-I, can be conjugated to PE to generate 
the lipid-conjugated form of LC3, or LC3-II, 
which becomes tightly associated with the 
autophagosomal membrane while the Atg5-Atg12 
conjugate is removed from the vesicle. Importantly, 
LC3-II can also return to an unlipidated state via 
the proteolytic activity of Atg4, suggesting that 
this process could be reversible. Other autophagy-
related proteins, like UV radiation resistance 
associated (UVRAG) and ATG9 were described 
to participate in autophagosome formation via 
their contribution in recruiting the PI3KC3-
Beclin1 complex to the autophagic precursor 
structures [176]. Of note, Atg14L and UVRAG 
bind to Beclin 1 in a mutually exclusive manner 
and ATG14L was shown to be critically required 
for autophagy induction [177, 178]. The UVRAG-
Beclin 1-PI3KC3 complex seems to modulate the
  
 
highly debated and may involve different sources 
such as endoplasmic reticulum (ER), mitochondria, 
Golgi, plasma membrane and recycling endosomes 
[149]. Phagophores engulf cytoplasmic material 
through membrane elongation and the formation 
of autophagic vacuoles, called autophagosomes 
[148, 150, 151]. Then, autophagosomes fuse with 
lysosomes to form autolysosomes. Before this 
step, autophagosomes can also fuse with endosomes 
to form amphisomes, making a direct connection 
between the endo-lysosomal and autophagic 
pathways. Upon degradation of the sequestered 
material by lysosomal hydrolases, constituents are 
recycled through lysosomal transporters toward 
the cytosol [152, 153]. It is important to note that 
several autophagy-related proteins might have 
autophagy-independent functions, including cell 
division, cell death, regulation of the inflammatory 
immune response and resistance to pathogens 
[154-156].  
Several specific protein complexes are successively 
involved in this process (Figure 1) (for reviews, 
[157-159]). The first complex involved in the 
initiation step of autophagy is the ULK1/2 
complex, composed of ULK1/2, Atg13, Atg101 
and FIP200 ([160, 161] for review). It is under the 
control of the mammalian target of rapamycin 
(mTOR) complex 1 (MTORC1) [162], which 
represses autophagy under nutrient rich conditions 
whereas, in most instances, AMP-activated 
protein kinase (AMPK) activation can inversely 
promote autophagy initiation ([161] for review). 
Of note, The ULK1/2 complex controls the 
trafficking of Atg9 from the plasma membrane to 
phagophores [163].  
The second complex is composed of class III 
phosphatidylinositol 3-kinase (PI3KC3), Beclin 1, 
p150 and Atg14L, which produces an autophagy-
specific pool of phosphatidylinositol 3-phosphate 
(PI3P) [164, 165]. Several additional proteins 
interacting with Beclin 1 ensure a timely and 
spatial regulation of PI3P formation during the 
autophagy process. These proteins can act as 
autophagy repressors, such as Bcl-2 present in the 
ER, or as autophagy stimulators, such as Ambra 1 
[166], WIPI2 [167] and DFCP1 (double FYVE 
domain containing protein 1) [168] and are the 
major effectors of the PI3P produced.  
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Figure 1. Overview of the autophagic pathway. 
The autophagic process begins by the formation, in the cytoplasm, of a double membrane called the phagophore. 
This structure elongates and sequesters cellular constituents such as organelles, proteins and pathogens. After the 
phagophore closure, the vacuole called autophagosome can fuse with a lysosome in order to digest and recycle the 
sequestered material. Autophagy is connected to endocytosis because autophagosomes can fuse with endosomes, to 
form amphisomes, which then fuse with lysosomes.  
Three signaling complexes are involved in the induction, the elongation and the closure steps of autophagy, leading 
to the formation of autophagosomes: 
-  The ULK complex, composed of ULK1/2-Atg13-FIP200-Atg101, responsible for autophagy initiation, is 
regulated by the mTOR kinase. 
- The class III PI3Kinase, associated with p150 and Beclin 1 (core complex), is responsible for the formation of 
the phagophore. Ambra1 and Bif-1 are essential for induction of autophagy, through direct interaction with 
Beclin 1 and UVRAG, respectively, whereas Bcl-2 binds to Beclin 1 and disrupts the Beclin 1-associated PI3K 
class III complex, thereby inhibiting autophagy. 
- Two ubiquitination-related conjugation systems leading to the formation of the Atg12-Atg5-Atg16L complex 
and the LC3-II-PE complex, are required for the elongation and closure of the autophagosome. Atg12 is 
conjugated to Atg5 by the action of the E1 enzyme Atg7 and the E2 enzyme Atg10. The resulting conjugate 
forms a complex with Atg16L. Likewise, Atg8, which is first processed by Atg4 is conjugated to a lipid, the 
phosphatidylethanolamine (PE), by the action of Atg7 and the E2 enzyme Atg3. The Atg12-Atg5-Atg16L 
complex acts as an E3 ligase facilitating the conjugation reaction of Atg8 to PE. 
The core complex containing UVRAG, is also involved at the level of fusion between autophagosomes and 
lysosomes. Rubicon inhibits this step by acting on UVRAG. 
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proteins, cell damage, production of reactive oxygen 
species (ROS), and/or mitochondrial depolarization, 
leading to autophagy induction. It was also 
recently shown that activation of RNase L during 
viral infections induces autophagy [197]. Autophagy 
could as well be induced upon engagement 
and stimulation of various pattern recognition 
receptors (PRR), including several Toll-like 
receptors (TLR) and the double-stranded RNA-
dependent protein kinase (PKR) [198, 199]. Viral 
proteins can also induce autophagy. For example, 
the non-structural measles virus protein C was 
shown to participate in autophagy induction upon 
viral replication [200] and the hepatitis C virus 
(HCV) nonstructural proteins 4B (NS4B), 5A 
(NS5A) and 5B (NS5B) were shown to co-localize 
with autophagosomal membranes or autophagy-
related proteins and positively regulate autophagy 
initiation [201, 202]. Recently, a study from the 
group of F. Randow demonstrated that the influenza 
viral protein M2 can redirect LC3 toward the 
plasma membrane supposedly to facilitate virion 
budding and stability [203]. Interestingly, viral 
replication concomitantly with the synthesis of 
viral proteins can increase energy requirements, 
thus triggering autophagy [204]. Finally, autophagy 
is indirectly triggered by IFN-  which supports its 
role in innate immunity, hence contributing to 
inflammation by facilitating an IFN-  response 
and signal transduction [205]. 
Since autophagy is a fundamental and general 
process involved in fighting viral infections, the 
viruses have evolved strategies to counteract or to 
exploit autophagy for their own benefit ([204, 
206-209] for reviews). In this review, we intend to 
describe several mechanisms by which viruses can 
manipulate autophagy. However, the relationship 
between a virus and the autophagy response is 
often more complex. Indeed, autophagy can be 
differentially subverted by viruses depending on 
target cells and viral strains. Pathogens can also 
sequentially block or control autophagy during 
their life cycle or take advantage of the formation 
of autophagy membrane while blocking the later 
step of lysosomal-mediated degradation.  Ultimately, 
viruses can also interfere with several autophagy-
related proteins without acting on the canonical, 
autophagy process. Because autophagy is involved 
in a complex cross-talk between cellular homeostasis
  
 
expansion and curvature of autophagosomal 
membranes, with the transient association of  
Bif-1 to UVRAG [179]. Another UVRAG-Beclin 
1-PI3KC3 complex plays a major role in the 
maturation step of autophagy [176, 180, 181] 
which could be negatively controlled by the RUN 
domain-containing protein Rubicon [178]. 
Autophagy has long been considered to be a 
nonselective bulk degradation pathway. However, 
there is growing evidence that it can act as a 
selective pathway leading to the degradation of 
specific organelles, such as mitochondria and 
peroxisomes, misfolded proteins and protein 
aggregates as well as pathogens. By definition, the 
selectivity should rely on a specific recognition 
of potential substrates. Indeed, this function is 
supported by cargo receptors that bind to both 
“eat-me” signals and Atg8 family members 
present on the autophagosomal membrane. The 
“eat-me” signals are generally molecules of 
ubiquitin, with the exception of galectin-8 present 
on bacteria [182]. Binding to Atg8 family engages 
a specific motif called a LC3-interacting region 
(LIR), with the general sequence W/F/YxxI/L/V 
preceded by acidic residues [183-188]. The first 
selective autophagy receptor to be identified was 
p62 (SQSTM1) [187, 189, 190], and then the 
related neighbor of BRCA1 gene 1 (NBR1) [191], 
nuclear dot protein 52 kDa (NDP52) [192] and 
optineurin [193]. A noncanonical LIR motif 
termed CLIR, which preferentially binds to LC3C 
was identified in the NDP52 sequence [194]. 
Several autophagy receptors specific for the 
degradation of mitochondria, termed mitophagy, 
have also been discovered ([195] for review).  
2.1. Autophagy during viral infections 
Autophagy is usually activated rapidly after a 
viral infection by different mechanisms depending 
on both viruses and host cells. The interaction 
between the virus and its receptors can directly 
trigger autophagy. This is the case for the 
attenuated strains of the measles viruses for which 
engagement of its cellular receptor triggers 
autophagy [196]. Furthermore, viral entry relying 
on a fusogenic envelope protein can also induce 
autophagy, as it is the case for HIV-1 and as 
described in section 3, subsection 3.1.1. Also, 
many viral infections trigger a cellular stress, such 
as ER stress, due to accumulation of unfolded 
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events leading to activation of the mTOR pathway 
correlated with inhibition of autophagy [222]. 
This would, however, need confirmation because 
in the same time another study reported a HPV-
16-mediated induction of antiviral autophagy 
upon infection of primary human keratinocytes 
[223]. 
Furthermore, specific degradation of viral 
components by autophagy has been described for 
only three viruses, the sindbis virus (SIN), the 
chikungunya virus (CHIKV) and the herpes 
simplex virus I (HSV-I). The sindbis capsid 
protein was shown to be targeted for autophagy 
degradation via the interaction with p62 and with 
the participation of the HECT domain-containing 
E3 ligase, Smad-ubiquitin regulatory factor 1 
(Smurf1), also important for the mitophagy 
process [224]. Smurf1 also appeared to be 
required for the degradation of HSV-I, but 
seemingly dispensable for general autophagy. 
Interestingly, the Ub E3 ligase domain of Smurf1 
is dispensable for its function in selective 
autophagy. In the same way, it has been shown 
that p62 binds to ubiquitinated capsid of CHIKV 
and targets it to autophagic degradation [225].  
Besides the direct role of autophagy in degrading 
viruses or viral components, autophagy can also 
stimulate the production of antiviral cytokines 
through production of type-I IFN. Indeed, in a 
cell-dependent context, virus-induced autophagy 
was shown to be important for the delivery of 
viral nucleic acids to endosomal and cytosolic 
PRR, thus contributing to the global innate 
immune response against invading pathogens. 
Interestingly, while autophagy was shown to be 
required for type I IFN secretion in response to 
DNA-immune complexes [226], a recent study 
reported that autophagy-related proteins could 
also be involved in the negative feedback regulation 
of innate immune responses due to the direct 
interaction between the cytosolic DNA sensor 
cyclic GMP-AMP (cGAMP) synthetase (cGAS) 
and Beclin-1 [227]. At a glance, the underlined 
mechanisms reveal a high level of complexity but 
the coincidental relationship between autophagy, 
inflammation and antiviral innate immunity 
warrants, undoubtedly, further investigation to 
appreciate all the parameters and cellular factors 
linked to autophagy involved in such processes. 
and apoptosis, usurping or modulating autophagy 
could therefore benefit viruses in controlling the 
survival of infected cells. 
2.2. Autophagy as an antiviral mechanism 
Autophagy is an essential pathway of host defense 
against viral infection that can degrade entire 
viruses or specific viral proteins by a process 
termed xenophagy [210]. 
There are growing reports on autophagy-dependent 
lysosomal-mediated degradation of viruses or 
viral components. Indeed, the autophagy pathway 
was reported to restrict infection in vivo by herpes 
simplex virus 1 (HSV-1) [211], sindbis virus 
(SIN) [212] and rift valley fever virus (RVFV) 
[213], although these observations were not fully 
recapitulated when investigating viral replication 
in vitro. This apparent discrepancy could be 
explained by the cellular-dependent context as 
well as by potential antiviral countermeasures 
developed by those viruses. Indeed, the importance 
of autophagy in antiviral immunity is strongly 
supported by the countermeasures and adaptations 
that viruses have evolved to dysregulate or limit 
specific steps of autophagy. For example, the viral 
protein ICP34.5 from HSV-1 and some viral 
proteins encoded by the -herpesviruses (HV68 
M11, KSHV vBcl-2) were reported to inhibit 
autophagy through a physical interaction with 
Beclin 1, thereby impeding autophagy initiation 
(reviewed in [214]). The conjugation of LC3 to 
PE was also shown to be impaired upon binding 
of the FLICE-like inhibitory protein (FLIP), 
encoded by the kaposi sarcoma-associated virus 
(KSHV), to Atg3 [215]. Later stages of autophagy, 
and particularly fusion with lysosomal 
compartments, could also be targeted by viruses 
as evidenced by the action of the HIV viral 
protein Nef [216], the influenza virus matrix 
protein 2 (MP2) [217] or the hepatitis B virus X 
protein (HBX) [218]. Additionally, human 
cytomegalovirus (HCMV) infection of human 
fibroblasts was reported to inhibit autophagosome 
formation [219, 220] and vaccinia virus (VV)-
mediated aberrant conjugation system and LC3 
lipidation were suggested to be the cause of 
autophagy inhibition [221]. Also, recent reports 
on human papillomavirus-16 (HPV-16) infection 
revealed that viral envelope-mediated signaling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
antigens [238, 255, 256] and also MHC-I cross-
presentation of antigens derived from dying or 
tumor cells [257, 258]. All these data therefore 
support a more selective process regulating 
autophagy-mediated antigen presentation, although 
the mechanisms brought into play in such a 
process require further investigation.  
Interestingly, some recent reports shine some light 
on the possible involvement of cell surface PRR 
in driving specificity toward autophagy-mediated 
lysosomal degradation which could thus regulate 
antimicrobial immunity [249, 259]. 
2.3. Autophagy as a pro-viral mechanism 
Several data converge toward the fact that viruses, 
mainly RNA ones, can use autophagy-related 
organelles as replication platforms, thereby 
promoting viral replication. Interestingly, some of 
them, including coxsackievirus B3 [260, 261] and 
rotavirus [262] are able to induce autophagy while 
blocking the fusion between autophagosomes 
and lysosomes to avoid their degradation. Some 
viruses, including dengue virus, poliovirus and 
CHKV seem to require the whole autophagy 
process in defined cell types, i.e., the acidic 
maturation step (for review [263]), while others 
might require only components of cellular 
autophagy, like for the murine hepatitis virus 
(MHV) [264] although this was not confirmed by 
others [265]. 
Induction of programmed cell death is also an 
important host defense mechanism against 
intracellular pathogens. Indeed, for a multicellular 
organism, it is advantageous to let infected cells 
die to thwart viral replication and dissemination. 
Considering the numerous interconnections between 
autophagy and apoptosis [266], and the fact that 
autophagy was already shown to contribute to cell 
survival after different stresses, including infections 
[209], virus-induced autophagy may thus counteract 
the antiviral effect of apoptosis by keeping 
infected cells alive until the viral replication cycle 
has been completed. This phenomenon was shown 
for several viruses, such as the human parvovirus 
B9, the influenza A virus, CHIKV, and SIN, 
as they can downregulate apoptosis through 
activation of autophagy [212, 267-269]. 
Autophagy is also a recycling pathway that 
provides free amino acids or fatty acids from 
 
While autophagy can be an important component 
of innate antimicrobial immunity, it is becoming 
clear that this pathway and associated autophagy-
related proteins are readily involved in the 
regulation of antigen processing and adaptive 
immune responses. It is already known that MHC-
II-mediated presentation of endogenous antigens 
was dependent on cytoplasmic proteases, including 
the proteasome and calpain as well as non-
proteasomal proteases [228, 229]. Interestingly, 
previous studies reported that autophagy was 
regulating the trafficking of the invariant chain li, 
a specialized MHC II chaperone, towards endo-
lysosomal compartments [230] and an inhibitor 
of autophagy could prevent MHC-II-mediated 
presentation of the biosynthesized endogenous 
fifth component of mouse complement C5 [231]. 
This suggests that autophagy flux modulation was 
regulating the intracellular antigen flux toward 
lysosomal compartments before reaching MHC-II 
molecules. Thereafter, major publications reported 
that autophagy flux modulation was indeed 
influencing MHC-II cross-presentation of 
endogenous antigens [232-235], reinforcing the 
hypothesis of a non-proteasomal proteolytic 
machinery involved in cytosolic or nuclear antigens 
presentation by MHC-II molecules. Further 
consolidating evidence came from data showing 
that the viral protein MP1 from influenza fused to 
LC3 led to an increased MHC class II-mediated 
antigen presentation to influenza-specific CD4+ T 
cell clones [236]. These observations were 
supported by other models of viral infection [235, 
237-239], bacterial infection [234, 240, 241] and 
even in the context of thymocytes selection driven 
by intracellular self-antigens loaded on thymic 
epithelial cell MHC-II molecules ([242-244] and 
see Figure 2). Of note, another autophagy-related 
process, CMA, was also reported to facilitate 
MHC-II-mediated presentation of cytoplasmic 
antigens in B cells via the lysosomal Lamp2A/ 
Hsc70 complex [245]. 
Autophagy-related organelles and proteins were 
also known to intersect with internalized pathogens 
and endocytic trafficking [246-248], possibly 
also involving this pathway in extracellular 
antigen presentation. Indeed, it seems clear now 
that autophagy can also regulate conventional 
MHC-II-mediated antigen presentation [249-254], 
MHC-I-mediated presentation of endogenous
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primary interface between viruses and CD4+ 
T cells. Interestingly, the majority of cells dying 
during HIV-associated disease progression are not 
infected. In accordance, several studies have 
demonstrated that infected cells expressing Env at 
the cell surface, are able to induce apoptosis of 
bystander uninfected CD4
+ T lymphocytes upon 
binding to either CXCR4 or CCR5 [56, 273-275].  
There are multiple cross-talks between autophagy 
and apoptosis. We have demonstrated that 
Env expressed on HIV-infected cells induces 
autophagy, subsequently required to trigger CD4
+ 
T cell apoptosis [276]. Indeed, the blockade of 
autophagy at different steps, by either drugs (3-
methyladenine or Bafilomycin A1) or by short 
interfering RNAs specific for beclin 1/atg6 and 
atg7 genes, inhibited the Env-induced apoptotic 
process. Even if the presence of CD4 and the co-
receptor on uninfected target cells was required 
for Env-mediated autophagy, this process was 
independent of these receptors signalling pathways 
but rather depended on the gp41 fusion activity 
[277]. Both hemifusion and complete fusion, 
which leads to the formation of syncytia triggered 
autophagy in bystander CD4
+ T cells. Notably, the 
deletion of the C-terminal part of gp41 enhanced 
Env-induced autophagy and apoptosis [277].  
Recently, Doitsh et al. have identified a new 
mechanism of uninfected CD4+ T cell death 
during HIV-1 infection called pyroptosis, defined 
as a caspase-1-mediated cell death involving the 
release of pro-inflammatory cytokines. Pyroptosis 
could be triggered by abortive viral infection in 
quiescent lymphoid CD4
+ T cells [58]. It would 
be interesting to analyze the possible involvement 
of autophagy in pyroptosis-associated uninfected 
CD4+ T cell death. 
3.1.2. Autophagy in productively infected CD4+           
T lymphocytes 
After its entry in CD4+ T lymphocytes, the RNA 
viral genome of HIV-1 is retro-transcribed into 
DNA before integration into the host cell genome. 
In quiescent naive CD4
+ T cells, this last step does 
not occur and in this case, autophagy-dependent 
cell death would occur. In contrast, activated 
CD4
+ T cells are permissive to HIV replication 
with de novo production of viral particles. 
Interestingly, in these productively infected CD4+
degradation of proteins or lipids, respectively. 
These new metabolites are then reused either as 
sources of energy or building blocks for the 
synthesis of new macromolecules. The dengue 
virus is the only one described until now that 
exploits the recycling function of autophagy. Its 
infection induces lipophagy (selective degradation 
of lipids droplets by autophagy) and thus release 
of free fatty acids, which undergo -oxidation in 
mitochondria to generate adenosine triphosphate 
(ATP) [270]. 
Even if many viruses may utilize autophagy to 
degrade host restriction factors or to maturate 
proteins involved in the viral life cycle, the data 
available are very few. One example is the 
cleavage of the capsid protein VP0 of the 
poliovirus in autolysosomes, leading to the 
maturation of a noninfectious virus to an infectious 
one [271]. 
3. Autophagy during HIV-1 infection 
Data on the relationships between HIV-1 and 
autophagy are still fragmentary and further 
investigation is required. However, from the 
current literature, autophagy is recognized as an 
important anti-HIV-1 process manipulated by the 
virus for its own replication. This process is at the 
center of the innate and adaptive immune 
responses against HIV-1. Its regulation depends 
on the cell type (CD4+ T cells, macrophages or 
dendritic cells) and the status of the cells (i.e., 
infected or non-infected cells). However, several 
Atgs including Atg7, Atg12, Atg16L, and 
GABARAPL2 appear to be required for HIV-1 
infection [272] and strikingly, autophagy is 
also responsible for Env-mediated apoptosis of 
bystander CD4+ T cells.  
3.1. Regulation of autophagy in CD4
+
 T cells  
3.1.1. Autophagy in uninfected CD4+ T lymphocytes 
HIV-1 infection is characterized by a progressive 
decline in the number of CD4+ T lymphocytes in 
untreated infected patients, ultimately leading to 
AIDS. Several mechanisms induced by HIV-1 
infection are involved in the death of these cells 
by apoptosis, and Env exerts a major role in this 
process. HIV-Env can be considered as a 
pathological ligand as its interaction with cellular 
receptors (CD4, CCR5 or CXCR4) constitutes the
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T cells, autophagy appeared to be completely 
blocked [278-280]. Indeed, after a co-culture 
between target CD4+ T cells and HIV-1-infected 
cells, two target cells populations were observed: 
a population of highly autophagic uninfected cells 
and a population of productively infected cells in 
which autophagy was impaired. Moreover, the 
level of LC3-II and Beclin 1 were dramatically 
decreased in the population of productively 
infected cells [279, 280]. These results suggested 
that a newly synthesized viral determinant, 
produced after the provirus integration step, was 
able to block autophagy [279]. Interestingly, 
induction of autophagy in productively infected 
CD4+ T cells with drugs acting on the MTORC1 
complex, decreased the production of new viral 
particles (our unpublished data), indicating that 
autophagy could behave as an anti-HIV process, 
however counteracted by the virus in order to 
replicate efficiently. To date, the mechanism by 
which HIV-1 could interfere with this essential 
cellular pathway is still under investigation. As 
seen before for other viruses, the way to 
understand the relationship between HIV-1 and 
autophagy is seemingly paved with complexity. 
Indeed, data from a genome-wide RNAi screen 
[272] and silencing of 30 candidate cofactors 
[281] indicated that HIV-1 replication in cells 
might require the presence of several Atgs (Atg7, 
GABARAPL2, Atg12, and Atg16L). A very 
recent study underlined the role of several Atgs, in 
particular Atg5 and Atg16, in HIV-1 replication in 
CD4+ T cells [282].  
It is worth noting that autophagy-related proteins 
can also function independently of the autophagic 
process, and this aspect has to be taken in 
consideration when trying to decipher the link 
between autophagy, autophagic proteins and 
HIV-1 infection. 
3.2. Regulation of autophagy in macrophages 
3.2.1. Autophagy in uninfected macrophages 
In contrast to bystander CD4+ T cells, autophagy 
induction was not observed in uninfected cells 
from the monocyte/macrophage lineage after 
contact with cells expressing HIV-1 R5 or X4 
Env, although these cells were definitely 
susceptible to autophagy induced by pharmacological 
means [279]. The state of differentiation was
  
seemingly not responsible for their intrinsic 
resistance to Env-mediated autophagy. Furthermore, 
Van Grol et al. demonstrated that the absence of 
autophagy observed in these target cells could be 
due to the simultaneous activation of Src-Akt 
and STAT3 by HIV-1 Tat and IL-10, pathways 
previously known to inhibit autophagy [283]. As 
Tat upregulates IL-10, the release of Tat from 
HIV-1- infected cells in the presence of increased 
concentrations of IL10 can lead to a blockade of 
autophagy in neighboring, uninfected macrophages, 
independently of the presence of Env and Nef 
[283]. HIV-1 Tat was also shown to perturb IFN-  
signaling in monocytes through the suppression of 
STAT1 phosphorylation [284] and consequently 
inhibiting MHC-II antigen expression. Recently, 
Li and collaborators demonstrated that Tat could 
suppress IFN- -induced autophagy in primary 
macrophages [285], suggesting that inhibition 
of autophagy could impair the immune defenses 
by blocking the antigen processing for the 
recognition and killing of intracellular pathogens. 
This result correlated well with the physiopathology 
of HIV-1 infection. Indeed, macrophages do not 
undergo Env-mediated apoptosis and are not 
subjected to depletion during HIV-1 infection. 
However, it raises many unsolved questions, 
including why the fusogenic function of gp41 
induces autophagy only in CD4+ T cells and why 
Tat and IL-10 do not inhibit autophagy in the 
bystander CD4+ T cells. While further investigation 
is needed to elucidate these major differences, one 
hypothesis would rely on the differential gp41-
induced perturbations triggered at the membrane 
of macrophages or CD4+ T cells. Indeed, HIV-1 
can enter macrophages by endocytosis, and 
additional specific interactions with host 
membrane molecules following Env binding to 
the receptor/co-receptor could be involved 
(described in the paragraph 1.2.). The functions of 
these two types of cells are also highly different, 
and macrophages are more prone to autophagy 
triggering than CD4+ T cells, which may also 
explain the observed differences. 
3.2.2. Autophagy in productively infected 
macrophages
Conversely, in cells from the monocyte/macrophage 
lineage, autophagy is induced following 
productive infection through contact with HIV-1 
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Figure 2
Figure 3
its absence is detrimental for viral production. 
IRGM also triggers autophagy in cells infected 
by other RNA viruses, such as Hepatitis C virus 
(HCV) and Measles virus (MeV), suggesting that 
different RNA virus families use similar strategies, 
involving IRGM, to fine-tune autophagy to their 
own benefit. 
In addition to HIV-1 proteins expressed through a 
transcript initiating from the promoter-harboring 
5’ long terminal repeat (LTR) region, antisense 
transcription leads to expression of the antisense 
protein ASP [290-293]. This protein is unstable 
in mammalian cells and seems to multimerize 
in vitro. ASP partially colocalizes with LC3 and 
preliminary data suggest that expression of ASP 
induces autophagy in the promonocytic U937 cell 
line and increases viral replication [294]. One 
hypothesis is that ASP might induce autophagy 
but then get degraded by autophagy as already 
shown for the human T-lymphotropic virus 
(HTLV) protein Tax, thus imposing a positive 
feedback on its own stability [295]. 
3.3. Regulation of autophagy in DC 
As mentioned above, the autophagy pathway can 
behave as an important effector of DC-mediated 
antiviral immunity. In the context of HIV-1 
infection of DC, an exhaustion of autophagy-
related organelles was rapidly observed upon viral 
challenge [249]. Interestingly, this was paralleled 
with the appearance of the compartmentalized virus 
evidenced hours after viral challenge [249, 250]. 
 
 
X4 or R5-infected effector cells [279]. Surprisingly, 
two populations of autophagic cells are present: 
one highly autophagic and the other weakly 
autophagic, and viruses could be detected in the 
weakly autophagic cells but not in the highly 
autophagic cells, suggesting that autophagy 
might still be controlled by HIV-1 in these cells to 
avoid degradation. Interestingly, the early steps of 
autophagy promoted HIV-1 production since 
blockade of this process dramatically decreased 
the quantity of HIV-Gag p24 [216, 279]. In 
addition, the HIV-1 precursor Gag was found in 
complexes with LC3 and was also present in  
LC3-II-enriched membranes, suggesting that 
autophagy could favor Gag processing and thus 
production of viral particles [216]. In contrast, the 
degradative step of autophagy behaves with anti-
HIV-1 activity and therefore, needs to be 
controlled by the virus to prevent its degradation. 
Indeed, blockade of the degradative step of 
autophagy increased HIV-1 production [216, 
279]. Interestingly, the auxiliary HIV-1 protein 
Nef was shown to play a major role in the 
inhibition of the degradative stage of autophagy 
by binding to Beclin 1 [216]. Nef also interacted 
with immunity-associated GTPase family M 
(IRGM), a protein known to play an autophagy-
dependent anti-bacterial function [286-288] and to 
bind to several key proteins of the autophagy 
process such as Atg5 and Atg10 [289]. Nef/IRGM 
interaction promoted autophagosome accumulation 
and improved HIV-1 replication [289]. In contrast,
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Legend to Figure 2. Crosstalks between autophagy and the immune systems during viral infection. 
A.  Autophagy and innate immunity: Autophagy can directly degrade intracellular pathogens after their 
sequestration in autophagosomes (xenophagy). It can also stimulate the production of type 1 IFN by allowing 
the delivery of viral nucleic acids to TLR7-containing endosomes. 
B.  Autophagy and adaptive immunity: Pathogenic antigens can be presented to CD4+ T lymphocytes by MHC II 
molecules after fusion of autophagosomes with MHC II-containing endosomes. Autophagosomes can allow the 
delivery of pathogenic antigens to MHC I molecules for a cross-presentation to CD8+ T lymphocytes. 
C.  Autophagy and homeostasis of the immune system: Autophagy is involved in both the positive and negative 
selection of CD4+ T lymphocytes, and in the differentiation and maintenance of B and T lymphocytes. 
Legend to Figure 3. Interactions between HIV-1 and autophagic proteins.  
The figure shows the complex relationship between the different HIV-1 and autophagic proteins in the different 
cellular types that constitute the HIV-1 target cells. The figure also illustrates the different autophagy modulation 
behavior of HIV-1 on its target cells according to their infection status (i.e. whether they were infected or not). 
Pathways leading to inhibition of autophagy are indicated in red, and those triggering autophagy are indicated 
in green.  
[249, 252]. Autophagy involvement in innate 
immunity was previously reported in pDC with 
the evidence that cytosolic viral replication 
intermediates could be transported into the 
lysosome by the process of autophagy and also 
regulate IFN-  secretion upon TLR7-mediated 
ssRNA recognition [308, 309]. Future studies on 
upstream cellular factors influencing viral trafficking 
through endocytic compartments linked to immune 
responses and intersecting with autophagy-related 
organelles are therefore required to better understand 
viral recognition mechanisms in DC, which could 
help in the design of vaccines. 
3.4. Regulation of autophagy in neuronal cells 
There is now compelling evidence that defects in 
neuronal intracellular trafficking is linked to 
neuropathologies [310]. In this light, the autophagy 
pathway is playing a key role in neuronal 
homeostasis as it is involved in clearance of 
protein aggregates that accumulate during aging 
and damaged organelles. Defects in this process 
are commonly found in neurodegenerative disorders 
[311]. Consistent with this, the autophagy machinery 
has been proposed to participate in HAND, even 
though conflicting data have been reported. 
Studies in patients and in transgenic mice expressing 
gp120 under an astrocyte-specific promoter have 
shown alteration in the autophagic pathway [312]. 
Young (under 50 years of age) patients had an 
increase in the level of key autophagy markers 
such as LC3 and Beclin 1, whereas these markers 
were decreased in older patients, suggesting a 
modification of the autophagy process during 
disease progression [312]. This report showed  
that aged gp120-expressing mice had reduced 
expression of autophagy markers and increased 
neurodegeneration compared to aged control 
animals [312]. Similarly, decreased autophagy has 
been reported in HIV-infected patients and SIV-
infected monkeys [313]. Supernatant from SIV-
infected microglia also led to decreased autophagy 
and alteration of autophagosome formation [314]. 
However, another study showed increased 
autophagic markers in HIV patient post-mortem 
brain samples, as well as in a neuronal cell lines 
exposed to gp120 [315]. Notably, increased 
expression/detection of markers such as LC3 can 
also be explained with a perturbed autophagic flux 
and not only with a global increase of autophagy.
  
 
Of note, there is now a growing line of evidence 
that autophagy-related organelles can intersect 
with internalized virions and behave as an early 
antiviral mechanism in myeloid cells [249, 296, 
297]. Even more interesting is the observation that 
DC-SIGN level of expression was linked to 
autophagy flux induction [298] and the receptor 
could traffic through autophagy-related organelles 
early upon engagement [249, 259]. The link 
between CLR and autophagy therefore warrants 
further investigation and might be of interest for 
future therapeutic strategies aiming at enhancing 
DC antiviral immune responses. 
Autophagy exhaustion correlates with a signaling 
cascade induced early upon HIV-envelope 
binding, leading to the activation of mTOR, a 
well-known inhibitor of autophagy flux initiation. 
However, the exact mechanism and upstream 
signaling effectors require further investigation. 
mTOR kinase is a target of numerous converging 
signaling pathways with implications on cellular 
growth, transcription and translation synthesis, 
autophagy flux regulation and cell survival (for 
review see [299]). Interestingly, there are now 
growing evidences that mTOR function and 
signaling are intriguingly connected to another 
amino acid sensor pathway converging toward the 
general control nonderepressible-2 (GCN-2) 
kinase. Of note, a link between inhibition of TOR 
signaling and activation of Gcn2 to phosphorylate 
eIF2  has been demonstrated in yeast [300]. In 
mammalian cells, some studies also reported some 
potential crosstalk between both pathways, 
although never related to DC-mediated antiviral 
immunity [301, 302] but still with implications in 
protective innate immune and stress responses 
upon bacterial infection [303, 304]. Outstandingly, 
GCN2 was recently reported to be a target of 
HIV-1 infection [305, 306] and was shown to 
exert antiviral effects against RNA viruses [307]. 
It would thus be of interest to decipher the 
potential crosstalk of the mTOR and GCN2 
pathways in the context of HIV-1 infection of DC 
and subsequent immune responses.   
In DC, reduction of autophagy was shown to 
impair TLR-mediated innate immune response 
[249] while also strongly affecting antigen 
processing and MHC-II-mediated antigen 
presentation to CD4+ T cells in vitro and in vivo
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enhancing the immune responses [297, 317-320] 
and may be used as antiviral compounds in 
association with HAART. 
First, sirolimus (rapamycin, Rapamune), a 
compound that strongly activates autophagy 
through inhibition of mTORC1 pathway, 
enhances the viral effects of HIV treatment. 
Sirolimus represses HIV-1 replication in vitro 
through different mechanisms including, but not 
limited to, the down regulation of CCR5 [321, 
322]. Although this was very surprising due to the 
known immunosuppressive action of sirolimus, 
the rapamycin effects might differ depending on 
the cell type targeted.  
Moreover, the group of B. Levine demonstrated 
that an autophagy activator peptide, composed of 
the Tat transduction domain attached to an 18 
amino acids sequence derived from the protein 
Beclin 1 that binds to Nef, decreases HIV-1 
replication in vitro [297]. Finally, chloroquine, a 
compound that blocks the fusion between 
autophagosomes and lysosomes, reduced HIV-1 
replication in vitro and the DC-DIGN-mediated 
HIV-1 transfer to CD4+ T cells [323].  
Modulation of the autophagy flux might thus 
be part of the currently developed therapeutic 
strategies against HIV infection as well as a 
promising approach to improve antiviral prophylactic 
regimen.  
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Definition
Autophagy is a fundamental and highly regulated lysosomal degradation mechanism, dependent on
specialized autophagy-related proteins (Atgs) (Mizushima et al. 2011). It can be classified into
macroautophagy, microautophagy, and chaperone-mediated autophagy, but only macroautophagy will
be described and hereafter referred to as autophagy since it is the major lysosomal route for the turnover of
cytoplasmic constituents. It is characterized by the formation of membranes that engulf cytoplasmic
material through the formation of autophagic vacuoles, called autophagosomes. These structures fuse
with lysosomes to form autolysosomes where the sequestered material is digested by lysosomal hydro-
lases. Before this degradative step, autophagosomes can also fuse with endosomes to form amphisomes,
making a direct connection between the endo-lysosomal and autophagic pathways. This process is highly
dynamic, and constituents are continuously recycled through lysosomal transporters toward the cytosol.
Autophagy plays essential physiological roles in survival, homeostasis, and development and is closely
linked to several mechanisms of cell death such as apoptosis, pyroptosis, and necroptosis. It is also
involved in the defense against invading intracellular pathogens and acts in both innate and adaptive
immunities.
Introduction
Autophagy has an essential role in cell homeostasis and has been implicated in several pathologies
including cancer, neurodegeneration, and myopathies. It is a constitutive mechanism further induced by
different stresses or stimuli that are dangerous for the cell. For example, autophagy is essential to provide
energy and amino acids during starvation. It also prevents cell death or senescence due to accumulation of
defective organelles, in particular damaged mitochondria, and large macromolecular aggregates.
The global autophagy process is presented in Fig. 1.
It requires several specific protein complexes regulating different steps of the autophagy flux (for
review (Ravikumar et al. 2010)).
The ULK1/ULK2 complex is involved in the initiation step of autophagy. The function of this multi-
protein complex, composed of ULK1/ULK2, Atg13, Atg101, and FIP200, is tightly controlled by the
mammalian target of rapamycin (mTOR) complex 1 (MTORC1), which represses autophagy flux
initiation under nutrient-rich conditions.
The second complex is composed of class III phosphatidylinositol 3-kinase (PI3KC3), Beclin 1, p150,
and Atg14L, which produces an autophagy-specific pool of phosphatidylinositol 3-phosphate (PI3P).
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*Email: Martine.biard@cpbs.cnrs.fr
Encyclopedia of AIDS
DOI 10.1007/978-1-4614-9610-6_395-1
# Springer Science+Business Media New York 2015
Page 1 of 7
Several additional proteins interacting with Beclin 1 ensure a timely and spatial regulation of PI3P
formation during the autophagy process.
Then, two unique ubiquitin (Ub)-like conjugation systems drive the elongation and closure of the
autophagic membrane. In the first conjugation system, Atg12 is conjugated to Atg5, in a reaction
mediated by the Ub-activating enzyme (E1)-like Atg7 and the Ub-conjugating enzyme (E2)-like
Atg10. No specific and exclusive Ub ligase (E3)-like has been discovered so far. Atg16L1 interacts
with the Atg12–Atg5 conjugate to form a scaffold necessary for LC3 lipidation. The second conjugation
system leads to the conjugation of proteins of the Atg8 family to the lipid phosphatidylethanolamine
(PE) through a mechanism controlled by Atg7 and Atg3, another E2-like enzyme. The Atg12–Atg5
conjugate is an E3-like for the Atg8–PE conjugation reaction. In humans, the Atg8 family comprises three
microtubule-associated protein 1 light chain 3 (LC3A, LC3B, and LC3C), one gamma-aminobutyrate
receptor-associated protein (GABARAP), and three GABARAP-like proteins (GABARAPL1–3). How-
ever, only LC3B has been extensively studied and will be hereafter referred to as LC3. LC3 is synthesized
as pro-LC3 and is very rapidly processed by the protease Atg4 to expose its C-terminal glycine. During
autophagosome formation, a fraction of this cytosolic, soluble form of LC3, also called LC3-I, can be
conjugated to PE to generate the lipid-conjugated form of LC3, or LC3-II, which becomes tightly
associated with the autophagosomal membrane while the Atg5–Atg12 conjugate is removed from the
neo-formed vesicles. Interestingly, LC3-II can also return to an unlipidated state via the proteolytic
activity of Atg4, indicating, therefore, that this process could be reversible, although its functionality is
not yet understood.
In turn, Beclin 1 recruits several proteins such as UVRAG and PI3KC3 to form a complex that plays a
major role in the maturation step of autophagy. This complex is negatively controlled by the RUN
domain-containing protein Rubicon. It is worth noting that Beclin 1 interacts with the antiapoptotic
protein Bcl2, as well as Bcl-XL, Bcl-w, and Mcl-1. Beclin 1 binding to Bcl2 represses autophagy when
Bcl2 is localized in the endoplasmic reticulum. Upon stress, Beclin 1 dissociates from Bcl-2, allowing the
activation of PI3KC3 and the subsequent stimulation of autophagy. This is one of the multiple links that
exist between autophagy and apoptosis. Although not yet fully investigated, other cross talks also exist
between autophagy and other programmed cell death pathways (necroptosis, pyroptosis) and the
Ub–proteasome system, the other main degradative pathway.
Fig. 1 Autophagy pathway
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Autophagy was first described as a nonselective bulk degradation pathway. However, specific forms of
autophagy can also selectively degrade cytoplasmic components such as organelles (e.g., mitochondria,
peroxisomes, lipid droplets, ribosomes) and proteins that can also be under aggregate forms.
This function is supported by cargo receptors (e.g., p62/SQSTM1, NBR1, and NDP52), which bind to
both “eat-me” signals, mainly molecules of Ub, and Atg8 family members present on the autophagosomal
membrane. Binding to Atg8 family engages a specific motif, called an LC3-interacting region (LIR), with
the general sequence W/F/YxxI/L/V preceded by acidic residues.
There is now a growing line of evidence that autophagy is also an essential pathway for host defense
against viral infection. Autophagy acts at different stages of antiviral immunity, including the degradation
of entire viruses or specific viral proteins by a process termed xenophagy, the activation of innate immune
signaling by delivery of viral nucleic acids to endosomal Toll-like receptors (TLRs), and the activation of
adaptive immunity by presentation of viral antigens to major histocompatibility complex (MHC) class
I and MHC class II molecules. As a consequence, the viruses have evolved strategies to counteract or to
exploit autophagy for their own profit.
HIV-1, as many other viruses, manipulates autophagy for its own replication. Its regulation depends on
the cell type (CD4+ T cells, macrophages, or dendritic cells) and the status of the cells (i.e., infected or
uninfected cells). This process is also at the center of the innate and adaptive immune responses against
HIV-1.
Autophagy is mainly an anti-HIV mechanism, although several Atgs, including Atg7, Atg12, Atg16L,
and GABARAPL2, are seemingly required for HIV-1 infection, as demonstrated through a functional
genomic screen using HeLa-derived TZM-bl cells (Brass et al. 2008). Several Atgs, in particular Atg5 and
Atg16, are also needed for HIV-1 replication in CD4+ T cells (Eekels et al. 2012), suggesting that either
HIV-1 needs the initiation step of autophagy or at least some of its components. It is worth noting that
autophagy-related proteins can also function independently of the autophagic process, and this aspect has
to be taken into consideration when trying to decipher the link between autophagy, autophagic proteins,
and HIV-1 infection.
Strikingly, autophagy is also responsible for the apoptosis of bystander CD4+ T cells triggered by
HIV-1 envelope.
Autophagy in CD4
+
T Cells During HIV-1 Infection
CD4+ T lymphocytes represent the main target cell population for HIV-1 infection, and their progressive
destruction is the hallmark of AIDS (Barré-Sinoussi et al. 1983). Depletion of this cell population is mainly
due to apoptosis of bystander uninfected CD4+Tcells (“▶Lymphocyte Apoptosis” and Finkel et al. (1995))
for which the viral envelope, composed of gp120 and gp41, plays an important role since it constitutes the
primary interface between viruses and target cells. In particular, the gp41-mediated fusion process occurring
during HIV-1 entry triggers activation of the intrinsic pathway of apoptosis, with activation of the caspases
9 and 3 (Roggero et al. 2001; Blanco et al. 2003; Garg and Blumenthal 2008). Recently, abortive HIV-1
infection, occurring in the vast majority of bystander quiescent CD4+ T cells, was shown to be responsible
for an inflammatory form of cell death, called pyroptosis (“▶Pyroptosis and HIV Replication”), charac-
terized by the activation of caspase 1 and the release of inflammatory cytokines upon viral DNA sensing by
the interferon-g-inducible protein 16 (IFI16) (Doitsh et al. 2014; Monroe et al. 2014).
Importantly, autophagy is also activated in bystander CD4+Tcells after their contact with infected cells,
through the gp41-dependent fusion of both membranes, and leads to their apoptosis (Espert et al. 2006;
Denizot et al. 2008). Autophagy contributes, therefore, to the depletion of CD4+ T cells during HIV-1
infection.
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Autophagy is an anti-HIV-1 process by specifically degrading Tat, a viral protein essential for viral
replication (Sagnier et al. 2015). As a consequence, autophagy is repressed in productively infected cells.
Very recent data indicate that autophagy in CD4+ T cells could be indeed targeted by the viral protein Vif
upon specific binding to the autophagy-related protein LC3 (Borel et al. 2015) (Fig. 2, left part).
Autophagy in Macrophages During HIV-1 Infection
In contrast to CD4+ T cells, bystander macrophages do not undergo autophagy after contact with HIV-1
envelope (Espert et al. 2009). This blockade is dependent on the activation of Src–Akt and Stat 3 by HIV-1
Tat and IL-10, both previously reported to inhibit autophagy (Van Grol et al. 2010). HIV-1 Tat was also
shown to suppress IFN-g-induced autophagy in primary macrophages (Li et al. 2011), suggesting that
inhibition of autophagy could negatively impact on innate immune defenses of myeloid cells devoted in
the killing of intracellular pathogens. Overall, this result correlated well with the physiopathology
reported from HIV-1-infected patients. Indeed, macrophages do not undergo Env-mediated apoptosis
and are seemingly not subjected to depletion during HIV-1 infection, at least compared to the level of
CD4+ Tcell depletion. These observations raise many relevant but still unsolved questions, including why
the fusogenic function of gp41 induces autophagy only in CD4+ Tcells and why Tat and IL-10 would not
inhibit autophagy in bystander CD4+ T cells.
Conversely, in cells from the monocyte/macrophage lineage, autophagy is induced following a
productive infection (Espert et al. 2009) and acts as an antiviral mechanism (Espert et al. 2009; Kyei
et al. 2009). Surprisingly, two populations of autophagic cells are present, one highly autophagic and the
Fig. 2 Relationship between autophagy and HIV-1 infection of its main target cells, namely, CD4+ T cells, macrophages, and
dendritic cells
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other weakly autophagic, and viruses could be detected in the weakly autophagic cells but not in the
highly autophagic cells, suggesting that autophagy might still be controlled by HIV-1 in these cells to
avoid degradation (Espert et al. 2009). Indeed, Nef regulates autophagy in these cells by two ways. First,
Nef binds to the immunity-associated GTPase family M (IRGM), inducing autophagy (Gregoire
et al. 2011), and second, Nef binds to Beclin 1, blocking the degradative step of autophagy (Kyei
et al. 2009).
The dual interaction of HIV-1 with autophagy thus enhances viral yields by using the early stages while
inhibiting the late stages of autophagy (Fig. 2, central part).
Apart fromNef, the antisense protein ASP, produced from antisense transcription of the HIV-1 genome,
partially co-localizes with LC3. Preliminary data suggest that expression of ASP induces autophagy and
increases viral replication in the promonocytic U937 cell line (Torresilla et al. 2013).
Autophagy in Dendritic Cells During HIV-1 Infection
Although some dendritic cell (DC) subsets could differ in phenotype and functions, one of their hallmarks
is their propensity to regulate innate and adaptive immunity.
DC (DCs) are known to regulate innate and adaptive immunity, and most of the subsets express a
plethora of pathogen recognition receptors (PRR) (“▶ Pathogen Recognition Receptors (General)”)
facilitating their antigen sampling activity and contributing to their quickness in efficiently igniting
adapted immune responses. Some DC subsets were also reported to be involved in the early events of
HIV transmission. Even if they are mostly refractory to productive HIV infection, these cells can readily
internalize virions via different receptors expressed at the surface, like C-type (CD209/DC-SIGN) or
I-type (CD169/SIGLEC-1) lectins, and transmit them toward CD4+ T cells.
Upon viral challenge, autophagy is rapidly inhibited in DCs through the activation of mTOR by HIV-1
envelope. This autophagy blockade impairs Toll-like receptor-mediated innate immune response while
also strongly affecting antigen processing and MHC-II-mediated antigen presentation to CD4+ T cells
(Blanchet et al. 2010) (Fig. 2, right part) potentially limiting anti-HIV immune responses.
Conclusion
Taken together, these results suggest a complex, cell-type-specific relationship between HIV-1 and the
autophagic response and highlight the complexity of HIV-1 pathogenesis. Autophagy appears to play
different roles in controlling HIV-1 replication, depending on the cell type. In turn, HIV-1 has evolved
individualized strategies to manipulate autophagy in each cell type. Whatever the cells involved,
autophagy is unambiguously involved in HIV-1 pathogenesis, and more investigation on its antiviral
role should strengthen our understanding of the interplay between the virus and the host.
Further studies are needed to (i) decipher the mechanisms that are activated after gp41-dependent
membrane fusion during the entry of the virus leading to autophagy, (ii) understand the link between
autophagy and apoptosis or other cell death mechanisms in the bystander CD4+ Tcells, (iii) determine the
viral proteins responsible for the control of autophagy in the infected cells, and (iv) understand the
connections between autophagy and viral trafficking through endocytic compartments linked to immune
responses in DC.
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Modulation of the autophagy flux might thus be a promising approach to improve immunomodulatory
approaches to treat HIV-1 infection aimed to increase immune responses in complementation to HAART.
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